ABX-1431 inhibits the development of endometrial adenocarcinoma and reverses progesterone resistance by regulating the MGLL-ROS/AKR1C1 pathway

ABX-1431 inhibits the development of endometrial adenocarcinoma and reverses progesterone resistance by regulating the MGLL-ROS/AKR1C1 pathway | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Article ABX-1431 inhibits the development of endometrial adenocarcinoma and reverses progesterone resistance by regulating the MGLL-ROS/AKR1C1 pathway Jie Jiang, Chunping Qiu, Xiaohong Ma, Min Xia, Kui Guo, Lina Wei, and 2 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-1745135/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 23 Dec, 2022 Read the published version in Cell Death & Disease → Version 1 posted 10 You are reading this latest preprint version Abstract Endometrial cancer is a common gynecological malignancy. With the delay of female fertility, conservative treatment with progesterone has been an important option for patients trying to preserve reproductive function. However, the progesterone resistance becomes a huge challenge and it is urgent to clarify the mechanism so as to propose a potential target and inhibit the development of endometrial adenocarcinoma and progesterone resistance. MGLL, an important factor involved in lipid mobilization, is overexpressed in many tumors, however the biological function of MGLL in the development of endometrial adenocarcinoma and the process of progesterone resistance still remains unclear. In this study, we first found MGLL was highly expressed in endometrial adenocarcinoma specimens by bioinformatics analysis, RT-PCR and immunohistochemistry and then we found the expression was further increased in progesterone resistant samples. Through in vitro and in vivo experiments, we demonstrated that overexpression of MGLL promoted tumor proliferation, metastasis and the occurrence of progestogen resistance, knockdown MGLL inhibited tumor proliferation, metastasis and reversed progestogen resistance. In addition, knockdown of MGLL can sensitize endometrial adenocarcinoma cells to progesterone by affecting ROS generation and reducing the expression of AKR1C1. Finally, it was verified that ABX-1431, MGLL inhibitor, reversed progesterone resistance and enhanced the sensitivity of endometrial adenocarcinoma to progesterone both in vitro and in vivo. In conclusion, the high expression of MGLL is involved in the occurrence and development of endometrial adenocarcinoma and progesterone resistance. Targeted inhibition of MGLL by inhibitors may be an effective method for the treatment of progesterone resistance in endometrial adenocarcinoma. Endometrial adenocarcinoma Progesterone resistance MGLL AKR1C1 ABX-1431 Figures Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Figure 6 Figure 7 Introduction Endometrial carcinoma (EC) is one of the most common gynaecologic malignant tumors, ranking in 4th and 6th place of all cancers with respect to morbidity and mortality, respectively 1 . Endometrioid adenocarcinoma (EAC) is mainly associated with obesity, hypertension and other factors, about 5% of patients with EAC develop the disease before the age of 40, but in recent years, statistics have found that the proportion of patients with the disease before the age of 40 has increased to 10%, these patients are normally inclined to select progesterone-based therapy. Studies revealed that approximately 55% of EAC patients showed a complete response to conservative treatment that included medroxy-progesterone acetate (MPA), with a 47% recurrence rate 2 . Nevertheless, other studies have shown that more than 30% of EAC patients do not respond to MPA and acquired resistance to progesterone during the treatment 3 . In consequence, progesterone resistance has become an urgent clinical problem to be solved. In this study, we deeply explored the molecular mechanism of progesterone resistance in EAC, hoping to improve progesterone resistance and poor prognosis of it. Monoacylglycerol lipase (MGLL, also MAGL) is an enzyme belonging to the family of serine hydrolases that preferentially catalyzes the hydrolysis of mono-triglycerides to glycerol and fatty acids and specializes in the degradation of endocannabinoids to the major enzymes responsible for controlling and regulating the levels of this cannabinoid 4 , 5 . It has become more and more important as an integrated metabolic hub, which not only controls the level of 2-arachidonoylglycerol(2-AG), but also controls the level of other monoacylglycerides. In addition, it controls the free fatty acids produced by their hydrolysis as well as other levels with proinflammatory or tumorigenic effects from the further metabolism of fatty acids. Accumulating evidence suggests that MGLL promotes tumor invasion and metastasis by up-regulating tumorigenic signals 6 . In cancer cells, MGLL hydrolyzes monoacylglycerols into free fatty acids, maintains elevated levels of these molecules, and further converts them into different tumorigenic lipids such as lysophosphatidic acid (LPA), prostaglandin E2(PGE2) 7 , 8 . It is well-known that EAC is a malignant tumor associated with abnormal lipid metabolism, and MGLL may play an important role in it, our group found that MGLL was overexpressed in progesterone resistance cells compared to sensitivity cells in previous studies. However, the function of MGLL in EAC and progesterone resistance. ABX-1431 is an efficient inhibitor of MGLL which is identified and developed by Cisar et al 9 . Studies have shown that ABX-1431 inhibit MGLL obviously with dose-dependent in vitro. At present, ABX-1431 has positive clinical results 10 , 11 , and MGLL inhibitors have good prospects for application in a variety of human diseases. However, there is no researches associated with ABX-1431 in EAC. In the present study, we explored the function and mechanism of MGLL in the development of EAC and progesterone resistance by carrying out a range of experiments in vivo and in vitro . Meanwhile, we investigated the efficacy of ABX-1431 for reversing progesterone resistance so as to provide efficient treatment for clinic in EAC. Results MGLL is a key gene high expressed in EAC and correlated to the progesterone resistance We analyzed the microarray data of EAC progesterone-sensitive cell line(Ishikawa) and the EAC progesterone-resistant cell line(IshikawaMR), and the raw data arising from this analysis has been uploaded to the GEO database (reference: GSE121367). The threshold of differential genes was set at a adj.P < 0.005 and | fold change (FC)|≥3, a heat map was created to show the differentially expressed genes (Fig. 1 A). We found that the mRNA expression of MGLL in the IshMR cell line was higher than that in the Ish cell line (Fig. 1 B, C). Subsequently, we performed Western Blot and found that the expression of MGLL in IshMR cell line increased compared with Ish cell line (Fig. 1 D). We collected clinical specimens of endometrial adenocarcinoma/atypical hyperplasia from patients who treated with conservative progesterone for IHC experiments. According to clinical outcomes, the species were divided into 3 groups: complete response (CR), partial response (PR) and no response/progression disease (NC/PD). The staining of clinical specimens in the 3 groups before and after treatment showed that MGLL was expressed at low levels in the CR and PR group and there was no statistical difference before and after treatment. Furthermore, the expression of MGLL in the NC/PD group was significantly higher after treatment (Fig. 1 E). To detect whether MGLL expression altered in EAC development, we further analyzed the data of GSE183185, a matched EAC and adjacent data in GEO database, and the results showed that MGLL expression was significantly higher in tumors compared with adjacent tissues (Fig. 1 F). To verify the results from database, we analyzed MGLL mRNA level in 16 EAC/adjacent tissues, and the expression of MGLL was remarkedly up-regulated in EAC tissues compared to adjacent tissues (Fig. 1 G). These findings were consistent with those from clinical samples (Fig. 1 H). In summary, MGLL is a key gene high expressed in EAC and correlated to the progesterone resistance. MGLL promotes the proliferation and inhibits the apoptosis of EAC cells We detected the expression of MGLL in 5 EAC cell lines and found that MGLL was barely expressed in AN3CA cells and abundant expressed in HEC-1A(Fig. 2 A). Thus, we chose AN3CA and HEC-1A cell line to create MGLL overexpression model and knocked-out model respectively. Western Blot and RT-PCR confirmed successful overexpression and knock-down of MGLL (Fig. 2 B, C). Overexpression of MGLL in AN3CA cell promoted the proliferation through MTT, EDU and colony formation assays, while the ability was significantly inhibited upon knock-down of MGLL in HEC-1A cell line (Fig. 2 D, E, F). Flow cytometry assay was used to detect whether the expression of MGLL could affect apoptosis of EAC cells. The results showed that the proportion of apoptotic cells decreased in AN3CA cells with MGLL overexpression and knock-down of MGLL caused significant apoptosis of HEC-1A cells (Fig. 2 G). Then we performed Western Blot assay to detect the expression of proteins involved in cell cycle and apoptosis. Consistent with above assays, proliferation-related proteins including CyclinD1, CDK4 and anti-apoptotic protein Bcl2 were significantly higher in overexpressing MGLL cells, and pro-apoptotic protein such as cleaved-PARP and cleaced-caspase3 were increased in knock-down MGLL cells (Fig. 2 H). The results suggested that upregulation of MGLL promoted the proliferation and inhibited apoptosis of EAC cells. MGLL enhances the invasion and migration of EAC cells We further investigated whether MGLL affected metastasis of EAC cells. Transwell assay showed the invasion and migration abilities of AN3CA cells in MGLL overexpression group were significantly enhanced compared to the control group, and the abilities of HEC-1A cells in MGLL knock-down group were obviously suppressed (Fig. 3 A). As shown in Fig. 3 B, compared with AN3CA-PCMV-Ctrl cells, the migration speed of AN3CA-PCMV-MGLL cells was remarkedly faster, and that of HEC-1A-shMGLL cells was significantly slower than that of HEC-1A-shCtrl cells (Fig. 3 B). Epithelial mesenchymal transformation pathway (EMT) represents the change of cell metastasis ability, and the decrease of epithelial-related markers such as E-cadherin, β-catenin and ZO-1 indicate the activation of EMT pathway and the enhancement of cell metastasis ability 12 . Therefore, we tested the expression of related markers and found that epithelial-related markers were lower in AN3CA-PCMV-MGLL cell than AN3CA-PCMV-Ctrl cell and higher in HEC-1A-shMGLL than HEC-1A-shCtrl (Fig. 3 C). It indicated that MGLL could promote the migration and invasion of endometrioid adenocarcinoma cells. MGLL overexpression conteracts the sensitivity of EAC cells to progesterone We established Ish cells with MGLL overexpression using lentivirus and detected by Western blot and RT-PCR at the protein and mRNA levels (Fig. 4 A, B). MTT assays showed that the IC 50 of the Ish-PCMV-MGLL cells almost increased 3-fold compared with Ish-PCMV-Ctrl cells, after 48-hours of treatment with different concentrations of MPA. Ish-PCMV-MGLL cells exhibited a stronger viability at the same concentration of MPA (Fig. 4 C). The proliferation ability of Ish-PCMV-MGLL and Ish-PCMV-Ctrl cells treated with MPA at concentrations of 0 and 60µM for 48 h was detected by EDU assay. The results showed that the proliferation ability of Ish-PCMV-MGLL was increased (Fig. 4 D). Furthermore, the percentage of apoptotic cells was lower in the Ish-PCMV-MGLL group than in the Ish-PCMV-Ctrl after MPA treatment by flow cytometry (Fig. 4 E). Western blot was then carried out to detect the expression of proteins related to proliferation and apoptosis. Following MPA treatment, when compared with the Ish-PCMV- Ctrl group, the expression levels of CDK4, CyclinD1, and Bcl2, in the Ish-PCMV- MGLL group were significantly up-regulated while the expression of cleaved-PARP was significantly down-regulated (Fig. 4 F). We also detected the migration and invasion of cells in response to MPA through transwell assay, and the ability of Ish-PCMV-MGLL was significantly higher than that of the control group (Fig. 4 G). Subsequently, we established nude-mouse xenograft tumor models using Ish-PCMV-MGLL and Ish-PCMV-Ctrl cells. Results showed that MPA treatment showed unconspicuous inhibitory effect on the Ish-PCMV-MGLL tumors. However, in the Ish-PCMV-Ctrl group, MPA treatment significantly inhibit tumor growth (Fig. 4 G). In conclusion, the overexpression of MGLL was related to the occurrence and development of progesterone resistance in EAC. MGLL knockdown renders EAC cells more sensitive to progesterone We established IshMR-shMGLL cells by lentivirus transfection and investigated expression levels by Western blot and RT-PCR (Fig. 5 A, B). MTT assays showed that the survival rates of IshMR-shMGLL cells after 48-hours of treatment with different concentrations of MPA were lower significantly than those of the shCtrl group (Fig. 5 C). EDU assays showed that the DNA synthesis of IshMR-shMGLL cells declined sharply when treated with 0, 90µM of MPA compared with the control group (Fig. 5 D). Flow cytometry further revealed that the proportion of cells showing signs of apoptosis was significantly higher in IshMR-shMGLL group(Fig. 5 E). The detection of proteins related to proliferation and apoptosis further confirmed these experimental findings (Fig. 5 F). Transwell assays were performed to examine the migration and invasion ability of cells in response to MPA, and the capacity of IshMR-shMGLL was inhibited (Fig. 5 G). IshMR-shMGLL and IshMR-shCtrl nude-mouse xenograft tumor models were established and then treated with MPA. These experiments revealed that the IshMR-shMGLL group exhibited a greater extent of tumor shrinkage, while the IshMR-shCtrl group only exhibited a slight amount of shrinkage (Fig. 5 H). In summary, the suppression of MGLL in progesterone-resistant cells enhanced the sensitivity of cells to progesterone and reversed progesterone resistance. MGLL regulates AKR1C1 by mediating the generation of ROS to induce the progesterone resistance in EAC To further explore the mechanism underlying the effect of MGLL on biological function and progesterone resistance in EAC, we performed next-generation sequence (NGS) in IshMR-shMGLL and IshMR-shCtrl cells. We did Gene Ontology (GO) enrichment analyses for the altered gene and found that MGLL plays important roles in protein binding, membrane composition and so on (Fig. 6 A). Differential genes (DEG) threshold was set at a adj.P < 0.005 and |fold change(FC) |≥3. A volcano plot was created to show the differentially expressed genes. A heat map was also created to show the distribution of differentially expressed genes between two groups. From the graph, we found that MGLL might regulate AKR1C1(Fig. 6 B, C). We further confirmed the relationship between MGLL and AKR1C1 using The Cancer Genome Atlas (TCGA) database of EC (Fig. 6 D) and found that AKR1C1 was highly expressed in IshMR cell(Fig. 6 E). GSEA analysis indicated that MGLL was able to lead to alterations of hypoxic microenvironment within tumor cells (Fig. 6 F, G), and subsequently we found that MGLL led to an increase in ROS generation (Fig. 6 H). It has been documented that an increasing level of ROS could induce AKR1C1 expression. So we examined the effect of ROS on AKR1C1 (Fig. 6 I and Fig. 6 J) and verified that MGLL regulated AKR1C1 expression by CO-IP assay (Fig. 6 K). The above results demonstrated that MGLL regulated the expression of AKR1C1 by promoting the generation of ROS. To validate the above conclusions, we knocked down AKR1C1 in Ish-PCMV-MGLL cells by siRNA and then carried out rescue experiments to detect the sensitivity to MPA. The knockdown efficiency of AKR1C1 was verified by Western Blot assay (Fig. 6 L). The results of MTT assay and apoptosis assay showed that interfering with AKR1C1 in Ish-PCMV-MGLL cells restored the sensitivity to MPA (Fig. 6 M, N). To draw a conclusion, MGLL is involved in progesterone resistance in EAC by promoting the expression of AKR1C1. ABX-1431 inhibited the growth of EAC and reversed progesterone resistance in vitro by inhibiting the expression of MGLL Given that MGLL plays an important role in progesterone resistance, it is bold to hypothesize that targeted inhibition of MGLL by ABX-1431 may have significant therapeutic advantages. As shown in Fig. 7 A, ABX-1431 could inhibit the expression of MGLL, and the inhibitory effect became stronger with the increase of concentration and extension of time. We determined that the IC50 of ABX-1431 on IshMR cells was 27.35µM by MTT assay (Fig. 7 B). Then we tested the effect of ABX-1431 and MPA on the viability of IshMR cells through CCK8, and found that 30µM MPA alone had no significant inhibitory effect on the viability of IshMR cells, while 20µM ABX-1431 could significantly inhibit the viability of EAC cells. Moreover, treatment with ABX-1431 combined with MPA further reduced cell viability (Fig. 7 C). EDU was applied to detect the ratio of proliferating cells and showed that combination of treatment remarkedly inhibited proliferation (Fig. 7 D). The long-term effects of two drugs on the proliferation ability of progestin-resistant cells were determined by colony formation assay, and the results were consistent with MTT (Fig. 7 E). Apoptosis assay demonstrated that the combination of ABX-1431 and MPA for 48 hours, significantly promoted apoptosis compared with the control, MPA and ABX-1431 groups (Fig. 7 F). Together, these data suggested that ABX-1431 increased the sensitivity of EAC cells to progesterone. Co-treatment with ABX-1431 and MPA synergistically inhibited the proliferation of progesterone-resistant EAC in vivo In order to further verify the sensitizing effect of ABX-1431 on progesterone, IshMR cell xenograft models were established and treated with DMSO, MPA and/or ABX-1431, respectively. It was found that the combination of MPA and ABX-1431 significantly inhibited the growth of tumors compared with the control group and single drug group, and there was no significant difference in the body weight of mice among the four groups (Fig. 7 G). Consequently, we detected markers associated with cell proliferation and apoptosis through IHC assay and validated the same results (Fig. 7 H). It can be seen that in vivo, ABX-1431 was able to enhance the sensitivity of EAC to progesterone and inhibit the growth of tumors. Discussion In recent years, with the increasing incidence of endometrial adenocarcinoma (EAC) and the younger patients, more and more population tend to choose conservative treatment to preserve reproductive function. However, progesterone resistance is a difficult problem in the treatment of EAC. Many theories are related to progesterone resistance, such as PGR-ER imbalance theory and abnormal activation of multiple signaling pathway including PI3K-AKT, Nrf2-survivin and autophagy pathway 13 – 15 , but the specific molecular mechanism of progesterone resistance is still unclear. When progesterone resistance occurs in tumors, progestin can’t exert its anticancer effects, but shows the function of promoting cancer cell proliferation and metastasis. Therefore, it is urgent to explore the molecular mechanism related to progestogen resistance in order to reverse progestogen resistance, improve the prognosis of patients and preserve the reproductive function of young patients. In consideration of the problem, our group previously established progesterone resistance cell line based on Ishikawa cell and performed NGS in progesterone sensitivity cell (Ishikawa) and progesterone resistance cell (IshMR) 16 . In this study, we firstly analyzed the RNA-seq results of Ishikawa cell and IshMR cell and screened out that MGLL expression was significantly increased in progesterone resistant cell lines 17 . MGLL is a key hub in the lipid signaling network and has been found to be involved in the development of varieties of tumor, such as breast cancer and melanoma cancer 18 , 19 . Subsequently, we confirmed that the expression of MGLL was elevated in EAC through the analysis of paired sample data of EAC in GEO database and the detection of tumors and adjacent tissues of EAC patients in Qilu Hospital of Shandong University. Meanwhile, we further verified that MGLL expression was obviously increased in progesterone resistance cell line and samples. Therefore, we hypothesized that MGLL was highly expressed in EAC and has a correlation with progesterone resistance. Subsequently, we overexpressed and knocked down MGLL in EAC cell lines, respectively and conducted functional experiments in vivo and in vitro .We verified that MGLL could promote the proliferation and inhibit apoptosis of tumor cells. It has been confirmed in the literature that the expression of MGLL in the primary lesion is higher in deeper areas of the tumor, indicating that tumor cells overexpressing MGLL are more aggressive 19 . So we also focused on the metastatic ability of cells with different expression levels of MGLL and verified it. Moreover, several studies have shown that MGLL is able to act by regulating the EMT pathway 18 , 20 , so we verified that MGLL promoted the metastasis of EAC cells by regulating the EMT pathway. In order to determine whether MGLL plays an important role in progesterone resistance of EAC, we conducted functional studies by overexpressing and knocking down of MGLL in EAC progesterone-sensitive cell lines and progesterone-resistant cell lines, respectively. The results showed that MGLL significantly improved the viability of Ish cells treated with MPA and induced progesterone resistance. In contrast, knocked down MGLL inhibited the proliferative capacity of IshMR cells, making them sensitive to progesterone. The results in vivo were consistent with those in vitro. These results indicated that the different expression levels of MGLL in tumors could affect the sensitivity of EAC cells to progesterone. Therefore, we believed that MGLL can promote the progress of EAC and participate in the development of progesterone resistance in EAC. Then, we performed NGS in IshMR-shMGLL cells and control cells and found that AKR1C1 expression was significantly reduced in IshMR-shMGLL cells. The location of two genes in the heatmap suggested that MGLL may regulate AKR1C1. GSEA enrichment analysis showed that overexpression of MGLL resulted in the development of hypoxia in the tumor microenvironment. At present, it is generally believed that the contradiction between the rapid growth of tumor tissue and the incomplete vascular system in tumor tissue leads to insufficient oxygen supply in tumor tissue, presenting a hypoxia microenvironment 21 . Tumor cells metabolize energy through anaerobic glycolysis, resulting in the accumulation of lactic acid and increased production of reactive oxygen species. Tumor cells in hypoxia microenvironment can escape drugs targeted at cell division by producing ROS and lead the resistance 22 , 23 .So we further examined the effect of MGLL on ROS generation and found that MGLL overexpression could lead to increased generation of ROS in EAC cells. Several literatures have demonstrated that ROS can induce the expression of AKR1C1 24–26 , and our experiments obtained the same results in EAC. The aldosterone reductase superfamily(AKRs) is a nicotinamide adenine dinucleotide phosphate (NADPH) -dependent oxidoreductase, and previous studies have shown that AKR1C1 can degrade progesterone into metabolite 20α-DHP, which binds to the specific plasma membrane and affects mitosis and cytoskeletal formation 27 28 . Overexpression of AKR1C1 may lead to inhibiting the production of progesterone receptors(PGR) and affect progesterone action 29 . Therefore, we speculated that MGLL promotes the expression of AKR1C1 by regulating the generation of ROS in EAC cells and accelerates the degradation of progesterone, leading to the development of progesterone resistance. To test the hypothesis, we interfered with AKR1C1 expression in cells overexpressing MGLL and found that no progesterone-resistant effect occurred in the cells. The above results demonstrated that MGLL is involved in progestogen resistance in EAC by activating AKR1C1. Finally, in order to explore efficient strategies to reserve progesterone resistance in EAC, we selected MGLL inhibitor for experiments according to previous researches. ABX-1431 is a lead compound for clinical evaluation based on optimized activity and selectivity for multiple human protein tissues 9 . Currently, ABX-1431 has successfully completed phase I clinical trials showing that the compound is well tolerated and safe, and phase II clinical studies of ABX-1431 are ongoing 10 . Therefore, we selected ABX-1431 as a MGLL inhibitor to verify whether it could inhibit the proliferation of EAC and reverse progesterone resistance. MTT, EDU, clony formation and apoptosis assays proved that the application of ABX-1431 could not only inhibit the proliferation and promote apoptosis of EAC cells, but also sensitize the effect of progesterone. Therefore, we believed that the combination of ABX-1431 and progesterone could be used in clinical treatment to improve the sensitivity and efficacy of EAC patients treated conservatively with progesterone. In summary, it is the first study to confirm that MGLL is one of the key moleculars involved in the development of EAC and progesterone resistance.It acts by affecting the hypoxia microenvironment in tumor cells and then regulating the expression of AKR1C1. We hypothesize that the high expression level of MGLL could be considered as a standard biomarker to evaluate the efficacy of progesterone in EAC patients. Our data also demonstrate that application of ABX-1431, an inhibitor of MGLL, can reverse progesterone resistance in patients with EAC and can be expected to achieve targeted therapy. Combination of ABX-1431 and progesterone can reserve progesterone resistance effectively and may provide new therapeutic strategies for clinical practice. Materials And Methods Cell lines and cell culture Ishikawa cells (referred to throughout this paper as ‘Ish’), AN3CA, RL-95-2, HEC-1A and KLE cells were purchased from Shanghai Zhong Qiao Xin Zhou Biotechnology Co. Progesterone resistant cells which we referred to as IshikawaMR (or ‘IshMR’) were previously obtained by our group via the increasing MPA concentration gradient method 30 . Ish and IshMR cells were cultured in RPMI1640 medium (BI, USA) containing 10% fetal bovine serum (BI, USA), RL-95-2 and HEC-1A cells were routinely grown in M5A media, AN3CA cells were cultured in RPMI-DMEM medium (BI, USA), and all cell lines were cultured at 37°C in a 5% CO 2 humidified atmosphere. 10µM MPA was added to the medium containing the IshMR cells to maintain resistance. Western blot analysis Cells were collected, lysed using a mixture containing RIPA, PMSF, and NaF, and the supernatant was taken after centrifugation and sonication to determine the protein concentration using the BCA method (Tiangen Biotech Co., Ltd., Beijing, China). Protein was separated by SDS-PAGE and transferred to PVDF membranes (Millipore, Bedford, MA, USA). The band was cropped according to the weight of the target gene and placed in the antibody overnight, and placed in the secondary antibody for 2h at room temperature. Protein bands were detected by ImageQuant LAS4000 (General Electric Company, Boston, MA, USA) and quantified by ImageJ software. β-actin was detected as a loading control. Quantitative real‑time transcription‑polymerase chain reaction(qRT-PCR) Total RNA was extracted from cells or tissues and the concentration and purity was evaluated with a spectrophotometer (Thermo Fisher Scientific Inc., MA, USA). RNA was then reverse transcribed into cDNA (3000 ng/10µl reaction system). PCR reactions were then performed on a StepOne ™ PCR amplifier (Applied Biosystems, USA) with SYBR-green (TAKARA, Japan) in a 10µl reaction system; β-actin was used as a control. The primers used are shown in the Supplementary information (Supplement Table 1). Tissue samples and immunohistochemistry assays(IHC) The EAC and adjacent tissues for Western Blot, RT-qPCR and IHC were from patients with primary EAC without previous therapy from Qilu Hospital of Shandong University. We acquired tissues from 37 patients who underwent progesterone treatment at Qilu Hospital of Shandong University between 2010 and 2020. The tissues were collected from the Pathology Department at Qilu Hospital. These patients did not have any other diseases of the reproductive system. The pathological diagnosis of endometrial carcinoma or hyperplasia was made in accordance with the latest National Comprehensive Cancer Network (NCCN) guidelines. All patients received medroxyprogesterone acetate for at least 6 months and were followed up regularly. Complete response (CR) was defined as the absence of residual hyperplasia or cancer in more than 95% of the tissue. Partial response (PR) was defined as < 50% of residual hyperplastic glands. If more than 50% of residual hyperplasia was evident, and the extent of hyperplasia was similar to or worse than before progesterone treatment, then the patients were classified as no change(NC) or progressive disease (PD) 31 – 33 . All human tissue samples were dehydrated for 1h and dewaxed with xylene and ethyl alcohol. We then used a microwave antigen retrieval technique to repair antigen. We then stained the tissues antibodies against MGLL (1:300), ki67(1:500) and cleaved-casepase3(1:800). Positive staining was subsequently visualized with 3,3’-Diaminobenzidine (DAB) and counterstained with hematoxylin Detailed experimental and analytical methods for IHC were described previously 34 . Antibodies and agents Antibodies used in WB and IHC experiments were following: MGLL (Abcam, ab234701), CDK4 (Cell Signaling Technologies, #12790), Cyclin D1 (Cell Signaling Technologies, #2978), cleaved-PARP (Cell Signaling Technologies, #5625), Bcl2 (Cell Signaling Technologies, #4223), cleaved-casepase3 (Cell Signaling Technologies, #9664), EMT kit(Cell Signaling Technologies, #9782), β-actin (Cell Signaling Technologies, #4970), Ki67 (Abcam, ab92742),AKR1C1(Abcam,ab179448), mouse IgG (Cell Signaling Technologies, #7076), and rabbit IgG (Cell Signaling Technologies, #7074).Antibodies for Co-IP was MGLL(Proteintech,14985-1-AP) and AKR1C1(Abcam,ab179448).Medroxyprogesterone acetate(MPA) and ABX-1431 were obtained from Abcam and Selleck, respectively, and were both diluted in DMSO. CCK8 assays 0.3 × 10 4 cells were seeded into 96-well plates, and 10 µlCCK8 was added to each well after cell attachment, and OD550 absorbance was measured 1h later, as the first day, and then at the same time every day. MTT assays MTT assays were used to analyze cell viability and determine the 50% inhibitory concentration (IC 50 ); 0.3 × 10 4 cells were seeded into a 96-well plate, and different concentrations of MPA were added to it the next day. After culture for 48 h, 10µl MTT (5mg/mL in PBS) solution was added to each well, as if it had been incubated in an incubator for 4 h. Formazan crystals were dissolved in 150µl of dimethylsulfoxide (DMSO; Sigma-Aldrich, St Louis, MO, USA). The absorbance at OD550 was measured, and the inhibition rate of the drug on the cells was calculated. Colony formation assay 600 cells were seeded into 6-well plates, attached or treated with MPA, and cultured for about 5–14 days when the cell density was appropriate, the cells were fixed with methanol and stained with crystal violet (Beyotime, Beijing, China). Photographs were taken for statistics. EDU incorporation assays 0.6 × 10 4 cells were seeded into 96-well plates, and after adherent or addition of MPA treatment, cells were fixed and stained for proliferating cells using the EDU kit, and finally Hoechst -labeled cells were used for statistics. Evaluating cellular apoptosis by flow cytometry (FCM) After cells were attached or treated with MPA for 48h, cells were collected for apoptosis. Then, we performed a cell apoptosis assay using a FACS flow cytometer and a FITC Annexin V Apoptosis Detection Kit (BD Bioscience Pharmingen, San Diego, CA, USA); the kit was used in accordance with the manufacturer’s instructions. Finally, data were analyzed by Cell Quest software (Becton Dickinson, Franklin Lakes, NJ, USA). Transwell assay Transwell assays were performed in transwell inserts (8-µm pore size, BD Biosciences, USA) inserted into 24-well plates without or with Matrigel (BD Biosciences, USA). The upper chamber was coated with 200 µl of serum-free medium containing 8×10 4 cells (for migration) or 12×10 4 (for invasion), while the lower chamber contained 700 µL of medium supplemented with 20% FBS. After incubation at 37 ° C for the appropriate time, cells that had migrated to the lower surface of the membrane were fixed with methanol, stained with 0.5% crystal violet, and observed and quantified under a light microscope. Wound healing assay 20×10 4 cells were seeded into 24-well plates, and when the cell density reached 90%, the wound was scratched using a 10µl pipette tips, and the cells were cultured until they reached confluence and photographed at 0, 72, 144 h. Xenograft model Four-week-old female BALB/c mice were injected with 1×10 7 cells cells into the right armpit. When the tumor diameter was about 5 mm, they were randomly divided into 4 groups and treated with intraperitoneal injection of drugs according to the experimental design. For MPA, the dose was 100 mg/kg/ bodyweight; for ABX-1431, the dose was 1 mg/kg, and the control group received the same amount of DMSO. Mouse body weight and tumor size were measured every two days. Fifteen mice were treated with drugs, euthanized, and the tumors were removed. Tumor size = width 2 × length/2. The animal experiments in our study were approved by the Ethics Committee of Shandong University. Measure of ROS and inhibitor Intracellular hydrogen peroxide levels were measured using 2,7-dichlorodihydrofluorescein diacetate (DCFH-DA; Beyotime Biotechnology, China). The cultured cells were washed once and incubated with DCFH-DA (20 µM, 30 min). DHE fluorescence was detected with a fluorescence microscope. Experiments were performed using N-acetylcysteine (NAC) (Selleck Chemicals, Houston, TX, United States) as an ROS inhibitor. Statistical analysis Data were analyzed using GraphPad Version 7.0 software.Statistical significance was determined by Student's t tests, one-way analysis of variance (ANOVA) and two-way ANOVA. All experiments were repeated at least three times. Statistical significance was set at P < 0.05. Declarations Funding statement This work was supported by the National Natural Science Foundation of China [Nos. 81772778 and 81902654]. Author contributions statement J.J., C.P.Q, X.H.M and M.X. designed the paper. X.H.M and M.X performed and analyzed experiments and wrote the paper. K.G., R.S., Y.L. and W.L. analyzed part of data and reviewed the paper. J.J., C.P.Q, X.H.M. and M.X. designed, supervised, and analyzed experimental work and wrote the paper. Ethics statement All animal work procedures were approved by the Ethics Committee of the Shandong University Qilu Hospital. Declaration of interest statement The authors declare that they have no conflict of interest. References Siegel, R.L., Miller, K.D., Fuchs, H.E. & Jemal, A. Cancer statistics, 2022. CA Cancer J Clin 72 , 7-33 (2022). Ushijima, K. et al. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol 25 , 2798-803 (2007). Ferenczy, A. & Gelfand, M. The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia. Am J Obstet Gynecol 160 , 126-31 (1989). Blankman, J.L., Simon, G.M. & Cravatt, B.F. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol 14 , 1347-56 (2007). Chicca, A. et al. Chemical probes to potently and selectively inhibit endocannabinoid cellular reuptake. Proc Natl Acad Sci U S A 114 , E5006-E5015 (2017). Qin, H. & Ruan, Z.H. The role of monoacylglycerol lipase (MAGL) in the cancer progress. Cell Biochem Biophys 70 , 33-6 (2014). Nomura, D.K. et al. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 140 , 49-61 (2010). Viso, A., Cisneros, J.A. & Ortega-Gutierrez, S. The medicinal chemistry of agents targeting monoacylglycerol lipase. Curr Top Med Chem 8 , 231-46 (2008). Cisar, J.S. et al. Identification of ABX-1431, a Selective Inhibitor of Monoacylglycerol Lipase and Clinical Candidate for Treatment of Neurological Disorders. J Med Chem 61 , 9062-9084 (2018). Jiang, M. & van der Stelt, M. Activity-Based Protein Profiling Delivers Selective Drug Candidate ABX-1431, a Monoacylglycerol Lipase Inhibitor, To Control Lipid Metabolism in Neurological Disorders. J Med Chem 61 , 9059-9061 (2018). Deng, H. & Li, W. Monoacylglycerol lipase inhibitors: modulators for lipid metabolism in cancer malignancy, neurological and metabolic disorders. Acta Pharm Sin B 10 , 582-602 (2020). Pastushenko, I. & Blanpain, C. EMT Transition States during Tumor Progression and Metastasis. Trends Cell Biol 29 , 212-226 (2019). Gu, C. et al. Inhibiting the PI3K/Akt pathway reversed progestin resistance in endometrial cancer. Cancer Sci 102 , 557-64 (2011). Zhou, Q. et al. DACH1 suppresses epithelial to mesenchymal transition (EMT) through Notch1 pathway and reverses progestin resistance in endometrial carcinoma. Cancer Med 8 , 4380-4388 (2019). Liu, H., Zhang, L., Zhang, X. & Cui, Z. PI3K/AKT/mTOR pathway promotes progestin resistance in endometrial cancer cells by inhibition of autophagy. Onco Targets Ther 10 , 2865-2871 (2017). Li, W. et al. Comprehensive bioinformatics analysis of acquired progesterone resistance in endometrial cancer cell line. J Transl Med 17 , 58 (2019). Ma, X. et al. Fatostatin reverses progesterone resistance by inhibiting the SREBP1-NF-kappaB pathway in endometrial carcinoma. Cell Death Dis 12 , 544 (2021). Hu, W.R. et al. Monoacylglycerol lipase promotes metastases in nasopharyngeal carcinoma. Int J Clin Exp Pathol 7 , 3704-13 (2014). Baba, Y. et al. Expression of monoacylglycerol lipase as a marker of tumour invasion and progression in malignant melanoma. J Eur Acad Dermatol Venereol 31 , 2038-2045 (2017). Gong, X. et al. Monoacylglycerol Lipase (MAGL) Inhibition Impedes the Osteosarcoma Progression by Regulating Epithelial Mesenchymal Transition. Tohoku J Exp Med 256 , 19-26 (2022). Yang, G., Shi, R. & Zhang, Q. Hypoxia and Oxygen-Sensing Signaling in Gene Regulation and Cancer Progression. Int J Mol Sci 21 (2020). Romero, Y. & Aquino-Galvez, A. Hypoxia in Cancer and Fibrosis: Part of the Problem and Part of the Solution. Int J Mol Sci 22 (2021). Bao, M.H. & Wong, C.C. Hypoxia, Metabolic Reprogramming, and Drug Resistance in Liver Cancer. Cells 10 (2021). Burczynski, M.E., Sridhar, G.R., Palackal, N.T. & Penning, T.M. The reactive oxygen species--and Michael acceptor-inducible human aldo-keto reductase AKR1C1 reduces the alpha,beta-unsaturated aldehyde 4-hydroxy-2-nonenal to 1,4-dihydroxy-2-nonene. J Biol Chem 276 , 2890-7 (2001). Ciaccio, P.J., Jaiswal, A.K. & Tew, K.D. Regulation of human dihydrodiol dehydrogenase by Michael acceptor xenobiotics. J Biol Chem 269 , 15558-62 (1994). Burczynski, M.E., Lin, H.K. & Penning, T.M. Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase. Cancer Res 59 , 607-14 (1999). Nakajima, T. et al. Expression of 20alpha-hydroxysteroid dehydrogenase mRNA in human endometrium and decidua. Endocr J 50 , 105-11 (2003). Lewis, M.J., Wiebe, J.P. & Heathcote, J.G. Expression of progesterone metabolizing enzyme genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinoma. BMC Cancer 4 , 27 (2004). Ji, Q. et al. Selective loss of AKR1C1 and AKR1C2 in breast cancer and their potential effect on progesterone signaling. Cancer Res 64 , 7610-7 (2004). Wang, Y. et al. Roles of SIRT1/FoxO1/SREBP-1 in the development of progestin resistance in endometrial cancer. Arch Gynecol Obstet 298 , 961-969 (2018). Wang, S. et al. Mechanisms involved in the evolution of progestin resistance in human endometrial hyperplasia--precursor of endometrial cancer. Gynecol Oncol 88 , 108-17 (2003). Wang, Y. et al. Prolonged conservative treatment in patients with recurrent endometrial cancer after primary fertility-sparing therapy: 15-year experience. Int J Clin Oncol 24 , 712-720 (2019). Chen, X. et al. Aberrant survivin expression in endometrial hyperplasia: another mechanism of progestin resistance. Mod Pathol 22 , 699-708 (2009). Liu, Z. et al. Fractalkine/CX3CR1 Contributes to Endometriosis-Induced Neuropathic Pain and Mechanical Hypersensitivity in Rats. Front Cell Neurosci 12 , 495 (2018). Supplementary Table supplementary table 1 is not available with this version. Additional Declarations (Not answered) Supplementary Files WesternBlotoriginaldata.docx Cite Share Download PDF Status: Published Journal Publication published 23 Dec, 2022 Read the published version in Cell Death & Disease → Version 1 posted Editorial decision: revise 19 Jul, 2022 Review # 2 received at journal 18 Jul, 2022 Review # 1 received at journal 11 Jul, 2022 Reviewer # 2 agreed at journal 10 Jul, 2022 Reviewer # 1 agreed at journal 27 Jun, 2022 Reviewers invited by journal 24 Jun, 2022 Submission checks completed at journal 14 Jun, 2022 Unknown event 13 Jun, 2022 First submitted to journal 10 Jun, 2022 Editor assigned by journal 10 Jun, 2022 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-1745135","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Article","associatedPublications":[],"authors":[{"id":116031734,"identity":"060c271b-9dc3-40ab-aa94-aa1e8c4edbe4","order_by":0,"name":"Jie Jiang","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA8klEQVRIiWNgGAWjYDACdoaEA0CKmY2B+QADD0jkACEtzHAtbAlEa4EBHgPitPAdZnh44OeOWnY+9p7PH962Mcjx3Uhg/FyAR4vkYYaEg71njjOz8ZzdJjm3jcFY8kYCs/QMPFoMgFoO8LYdY2aTyN3GzNvGkLjhRgIbMw8BLQf/grTIv3n8Gailnigth3nbaoC28DBIA7UkGBDSAvLLYdm2A0C/pJlJzjknYTjzzMNmaXxa+I73JH9821aXLN9++PGHN2U28nzHkw9+xqeF4QBPApA8nAzlSgAxYwM+DUAt7AeAZJ0dflWjYBSMglEwogEAjaFNiP57cK8AAAAASUVORK5CYII=","orcid":"https://orcid.org/0000-0002-9634-4152","institution":"Qilu Hospital of Shandong University","correspondingAuthor":true,"prefix":"","firstName":"Jie","middleName":"","lastName":"Jiang","suffix":""},{"id":116031735,"identity":"2b9c8e97-a199-47a8-95fa-59e3a21e7088","order_by":1,"name":"Chunping Qiu","email":"","orcid":"https://orcid.org/0000-0003-4625-8165","institution":"Qilu Hospital of Shandong University","correspondingAuthor":false,"prefix":"","firstName":"Chunping","middleName":"","lastName":"Qiu","suffix":""},{"id":116031736,"identity":"c163af3b-403c-4b0a-90bd-f49d6a8de56f","order_by":2,"name":"Xiaohong Ma","email":"","orcid":"https://orcid.org/0000-0001-8625-237X","institution":"Qilu Hospital of Shandong University","correspondingAuthor":false,"prefix":"","firstName":"Xiaohong","middleName":"","lastName":"Ma","suffix":""},{"id":116031737,"identity":"bc1d7e09-a1ef-49a2-9d31-32cdc756f2bd","order_by":3,"name":"Min Xia","email":"","orcid":"","institution":"Qilu Hospital of Shandong University","correspondingAuthor":false,"prefix":"","firstName":"Min","middleName":"","lastName":"Xia","suffix":""},{"id":116031738,"identity":"eece76d2-3e9a-497a-9b73-93dc0991cc20","order_by":4,"name":"Kui Guo","email":"","orcid":"https://orcid.org/0000-0002-3594-3901","institution":"Qilu Hospital of Shandong University","correspondingAuthor":false,"prefix":"","firstName":"Kui","middleName":"","lastName":"Guo","suffix":""},{"id":116031739,"identity":"20624e59-eaed-4e6c-9305-15f33c1b6de8","order_by":5,"name":"Lina Wei","email":"","orcid":"","institution":"Qilu Hospital of Shandong University","correspondingAuthor":false,"prefix":"","firstName":"Lina","middleName":"","lastName":"Wei","suffix":""},{"id":116031740,"identity":"05a267d4-31e4-4592-97af-903822a43561","order_by":6,"name":"Rui Sun","email":"","orcid":"","institution":"Qilu Hospital of Shandong University","correspondingAuthor":false,"prefix":"","firstName":"Rui","middleName":"","lastName":"Sun","suffix":""},{"id":116031741,"identity":"587fca16-22be-4b1e-bb1a-c037d39ae37e","order_by":7,"name":"Yao Liu","email":"","orcid":"","institution":"Qilu Hospital of Shandong University","correspondingAuthor":false,"prefix":"","firstName":"Yao","middleName":"","lastName":"Liu","suffix":""}],"badges":[],"createdAt":"2022-06-10 11:00:38","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-1745135/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-1745135/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1038/s41419-022-05507-z","type":"published","date":"2022-12-23T05:00:00+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":23343938,"identity":"10990713-4690-47da-a7f0-b2945f0ab007","added_by":"auto","created_at":"2022-07-01 19:53:54","extension":"jpg","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":1673251,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eMGLL is a key gene high expressed in EAC and correlated to the progesterone resistance \u003c/strong\u003e\u003c/p\u003e\u003cp\u003e1A. Hierarchically clustered heatmap of differentially expressed genes in IshMR and Ish cells.\u003c/p\u003e\u003cp\u003e1B. Volcano plot of RNA-seq from microarray data in IshMR and Ish cells. The green dots represent DEGs based on a |FC| of≥3. The red dots represent MGLL.\u003c/p\u003e\u003cp\u003e1C. The violin plot depicting the expression distribution of MGLL between IshMR and Ish cells.\u003c/p\u003e\u003cp\u003e1D. MGLL protein level in Ish and IshMR cells.\u003c/p\u003e\u003cp\u003e1E. Representative images of IHC staining of MGLL in endometrium before and after progesterone treatment in CR, PR and NC/PD group. MGLL IHC scores in endometrium before and after progesterone treatment were analyzed by Image-Pro Plus 6.0. The Score= (percentage of cells of weak intensity × 1) + (percentage of cells of moderate intensity × 2) +(percentage of cells of strong intensity × 3).\u003c/p\u003e\u003cp\u003e1F. Validation of MGLL expression in EC and adjacent samples from GEO databases, GSE183185. The mRNA level of MGLL was analyzed with the “limma” package using Student’s t test.\u003c/p\u003e\u003cp\u003e1G. MGLL mRNA level in in 16 EAC tissues and its adjacent tissues.\u003c/p\u003e\u003cp\u003e1H. Representative images of IHC staining of MGLL in EAC and normal tissues. \u003c/p\u003e\u003cp\u003eCR: complete response. PR: partial response. PD/SD: progressive/stable disease. Ish: Ishikawa. IshMR: MPA-resistant cell line of Ish cells. *\u003cem\u003eP\u003c/em\u003e\u0026lt; 0.05, **\u003cem\u003eP\u003c/em\u003e\u0026lt; 0.01, ***\u003cem\u003eP\u003c/em\u003e\u0026lt; 0.001 and ****\u003cem\u003eP\u003c/em\u003e\u0026lt;0.0001 for statistical analysis of the indicated groups.\u003c/p\u003e","description":"","filename":"Figure1.jpg","url":"https://assets-eu.researchsquare.com/files/rs-1745135/v1/87c77d4573058b3a67aea14a.jpg"},{"id":23343939,"identity":"34e1048b-10e8-472c-9fe6-0c3ab318edaa","added_by":"auto","created_at":"2022-07-01 19:53:54","extension":"jpg","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":1595580,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eMGLL promotes the proliferation and inhibits the apoptosis of EAC cells\u003c/strong\u003e\u003c/p\u003e\u003cp\u003e2A. Expression of MGLL in Ishikawa, AN3CA, RL95-2, HEC-1A and KLE cells.\u003c/p\u003e\u003cp\u003e2B. Protein level of MGLL in AN3CA cell after MGLL knockdown and in HEC-1A cell after MGLL overexpressed.\u003c/p\u003e\u003cp\u003e2C. Protein level of MGLL in AN3CA cell after MGLL knockdown and in HEC-1A cell after MGLL overexpressed.\u003c/p\u003e\u003cp\u003e2D. Growth curves of cells after MGLL deletion or overexpression compared with control cells. \u003c/p\u003e\u003cp\u003e2E. The effect of MGLL inhibition on colony formation.\u003c/p\u003e\u003cp\u003e2F. Proliferation rates of cells overexpressing or knocking-out MGLL by EDU incorporation assay.\u003c/p\u003e\u003cp\u003e2G. Proportion of apoptotic cells presented by apoptosis assay in cells after overexpression or knockdown of MGLL.\u003c/p\u003e\u003cp\u003e2H. Expression of CDK4, Cyclind1, Bcl-2, cleaved-PARP and cleaved-caspase were determined by western blotting assay in EAC cells after overexpression or knockdown of MGLL.\u003c/p\u003e\u003cp\u003eAll experiments were repeated three times at least. *\u003cem\u003eP\u003c/em\u003e\u0026lt; 0.05, **\u003cem\u003eP\u003c/em\u003e\u0026lt; 0.01, ***\u003cem\u003eP\u003c/em\u003e\u0026lt; 0.001 and ****\u003cem\u003eP\u003c/em\u003e\u0026lt;0.0001 for statistical analysis of the indicated groups.\u0026nbsp;\u003c/p\u003e","description":"","filename":"Figure2.jpg","url":"https://assets-eu.researchsquare.com/files/rs-1745135/v1/b24b4710c8e139b133b53601.jpg"},{"id":23344250,"identity":"23f69640-6d2d-498c-9dc6-4587a0828b91","added_by":"auto","created_at":"2022-07-01 19:58:54","extension":"jpg","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":2375559,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cbr\u003e\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eMGLL enhances the invasion and migration of EAC cells\u003c/strong\u003e\u003c/p\u003e\u003cp\u003e3A. Migration and invasion after deletion or overexpression of MGLL in EAC cells by transwell assay.\u003c/p\u003e\u003cp\u003e3B. Migration after deletion or overexpression of MGLL in EAC cells by wound healing assay.\u003c/p\u003e\u003cp\u003e3C. Expression of E-cadherin, N-cadherin, vimentin, zo-1 and claudin-1 were determined by western blotting assay in EAC cells after overexpression or knockdown of MGLL.\u003c/p\u003e\u003cp\u003eAll experiments were repeated three times at least. *\u003cem\u003eP\u003c/em\u003e\u0026lt; 0.05, **\u003cem\u003eP\u003c/em\u003e\u0026lt; 0.01, ***\u003cem\u003eP\u003c/em\u003e\u0026lt; 0.001 and ****\u003cem\u003eP\u003c/em\u003e\u0026lt;0.0001 for statistical analysis of the indicated groups.\u0026nbsp;\u003c/p\u003e","description":"","filename":"Figure3.jpg","url":"https://assets-eu.researchsquare.com/files/rs-1745135/v1/0cb666a6941b598da0d3319d.jpg"},{"id":23343941,"identity":"52bf0118-7da5-4a95-bce9-2241765e78fb","added_by":"auto","created_at":"2022-07-01 19:53:54","extension":"jpg","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":1810061,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cbr\u003e\u003c/p\u003e\u003cp\u003e\u003cstrong\u003eMGLL overexpression conteracts the sensitivity of EAC cells to progesterone.\u003c/strong\u003e\u003c/p\u003e\u003cp\u003e4A. Western blotting assay was used to detect the protein expression of MGLL in Ish-PCMV-MGLL and Ish-PCMV-Ctrl cells.\u003c/p\u003e\u003cp\u003e4B. RT-PCR was used to detect the mRNA expression of MGLL in Ish-PCMV-MGLL and Ish-PCMV-Ctrl cells.\u003c/p\u003e\u003cp\u003e4C. MTT assay was used to detect the viability of Ish-PCMV-MGLL and Ish-PCMV-Ctrl cells with different-dose MPA.\u003c/p\u003e\u003cp\u003e4D. The proliferation capacity of Ish-PCMV-MGLL and Ish-PCMV-Ctrl cells with 0 or 60μm MPA treatment by EDU assay. \u003c/p\u003e\u003cp\u003e4E. Apoptosic cells in Ish-PCMV-MGLL and Ish-PCMV-Ctrl groups \u0026nbsp;with 0.60μM MPA for 48h respectively. Apoptosis was detected by flow cytometry after staining with FITC Annexin-V and PI. \u003c/p\u003e\u003cp\u003e4F. Expression of MGLL, CDK4, Cyclind1, Bcl-2, cleaved-PARP and cleaved caspase3 were determined by western blotting assay in Ish-PCMV-MGLL and Ish-PCMV-Ctrl cells were treated with 0.60μM MPA for 48h respectively.\u003c/p\u003e\u003cp\u003e4G. Migration and invasion in Ish-PCMV-MGLL and Ish-PCMV-Ctrl cells treated with 0.30μM MPA for 48h respectively by transwell assay.\u003c/p\u003e\u003cp\u003e4H. The left image shows the tumors transfected with Ish-PCMV-MGLL and Ish-PCMV-Ctrl treated with MPA or DMSO. The right image shows the tumor weights of the four groups of mice.\u003c/p\u003e\u003cp\u003eAll experiments were repeated three times at least. *\u003cem\u003eP\u003c/em\u003e\u0026lt; 0.05, **\u003cem\u003eP\u003c/em\u003e\u0026lt; 0.01, ***\u003cem\u003eP\u003c/em\u003e\u0026lt; 0.001 and ****\u003cem\u003eP\u003c/em\u003e\u0026lt;0.0001 for statistical analysis of the indicated groups.\u0026nbsp;\u003c/p\u003e","description":"","filename":"Figure4.jpg","url":"https://assets-eu.researchsquare.com/files/rs-1745135/v1/3b07d1ee186d9cba05bddce3.jpg"},{"id":23343943,"identity":"d88cfb2f-92c0-4383-949c-285a96f088a6","added_by":"auto","created_at":"2022-07-01 19:53:54","extension":"jpg","order_by":5,"title":"Figure 5","display":"","copyAsset":false,"role":"figure","size":1787878,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eMGLL knockdown renders EAC cells more sensitive to progesterone\u003c/strong\u003e\u003c/p\u003e\u003cp\u003e5A. Western blotting assay was used to detect the protein expression of MGLL in IshMR-shMGLL and IshMR-shCtrl cells.\u003c/p\u003e\u003cp\u003e5B. RT-PCR assay was used to detect the mRNA expression of MGLL in IshMR-shMGLL and IshMR-shCtrl cells.\u003c/p\u003e\u003cp\u003e5C. MTT assay was used to detect the viability of IshMR-shMGLL and IshMR-shCtrl cells with different-dose MPA.\u003c/p\u003e\u003cp\u003e5D. The proliferation capacity of IshMR-shMGLL and IshMR-shCtrl cells with 0 or 60μm MPA treatment by EDU assay. \u0026nbsp;\u003c/p\u003e\u003cp\u003e5E. Apoptosic cells in IshMR-shMGLL and IshMR-shCtrl groups with 0.60μM MPA for 48h respectively. Apoptosis was detected by flow cytometry after staining with FITC Annexin-V and PI.\u003c/p\u003e\u003cp\u003e5F. Expression of MGLL, CDK4, Cyclind1, Bcl-2, cleaved-PARP and cleaved caspase3 were determined by western blotting assay in IshMR-shMGLL and IshMR-shCtrl cells were treated with 0.60μM MPA for 48h respectively.\u003c/p\u003e\u003cp\u003e5G. Migration and invasion in IshMR-shMGLL and IshMR-shCtrl cells treated with 0.30μM MPA for 48h respectively by transwell assay.\u003c/p\u003e\u003cp\u003e5H. The left image shows the tumors transfected with IshMR-shMGLL and IshMR-shCtrl treated with MPA or DMSO. The right image shows the tumor weights of the four groups of mice.\u003c/p\u003e\u003cp\u003eAll experiments were repeated three times at least. *\u003cem\u003eP\u003c/em\u003e\u0026lt; 0.05, **\u003cem\u003eP\u003c/em\u003e\u0026lt; 0.01, ***\u003cem\u003eP\u003c/em\u003e\u0026lt; 0.001 and ****\u003cem\u003eP\u003c/em\u003e\u0026lt;0.0001 for statistical analysis of the indicated groups.\u0026nbsp;\u003c/p\u003e","description":"","filename":"Figure5.jpg","url":"https://assets-eu.researchsquare.com/files/rs-1745135/v1/b380536158a9cdc254f9dd61.jpg"},{"id":23344252,"identity":"75ad7c5e-d114-4c8d-886c-aefe0e449639","added_by":"auto","created_at":"2022-07-01 19:58:54","extension":"jpg","order_by":6,"title":"Figure 6","display":"","copyAsset":false,"role":"figure","size":1319958,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eMGLL regulates AKR1C1 by mediating the generation of ROS to induce the progesterone resistance in EAC\u003c/strong\u003e\u003c/p\u003e\u003cp\u003e6A. GO Enrichment of DEGs in IshMR-shMGLL and IshMR-shCtrl cells, including in GO-BP, GO-CC, GO-MF pathway analysis.\u003c/p\u003e\u003cp\u003e6B. Volcano plot of RNA-seq from microarray data in IshMR-shMGLL and IshMR-shCtrl cells. The blue and red dots represent DEGs based on a |FC| of≥3. The green dot represents AKR1C1.\u003c/p\u003e\u003cp\u003e6C. Hierarchically clustered heatmap of differentially expressed genes in IshMR-shMGLL and IshMR-shCtrl cells. AKR1C1 and MGLL are closely located in the heatmap.\u003c/p\u003e\u003cp\u003e6D. The relationship of MGLL and AKR1C1 in the TCGA database of EC.\u003c/p\u003e\u003cp\u003e6E. The violin plot depicting the expression distribution of AKR1C1 between IshMR and Ish cells.\u003c/p\u003e\u003cp\u003e6F. GSEA analysis revealed that hypoxia was enriched after knockdown of MGLL.\u003c/p\u003e\u003cp\u003e6G. GSEA analysis revealed that hypoxia was repressed in MGLL knockdown cells.\u003c/p\u003e\u003cp\u003e6H. The generation of intracellular ROS in different groups.\u003c/p\u003e\u003cp\u003e6I. Effects of NAC on ROS.\u003c/p\u003e\u003cp\u003e6J. The expression of AKR1C1 after inhibition of ROS.\u003c/p\u003e\u003cp\u003e6K. CO-IP experiments demonstrated that MGLL could regulate the expression of AKR1C1.\u003c/p\u003e\u003cp\u003e6L. Expression of \u003cem\u003eAKR1C1\u003c/em\u003e in Ish-PCMV-MGLL cells after transfected with si\u003cem\u003eRNA\u003c/em\u003e or siNC for 72 by Western blot assay.\u003c/p\u003e\u003cp\u003e6M. Growth curves in Ish-PCMV-MGLL cells with different-dose MPA by MTT assay.\u003c/p\u003e\u003cp\u003e6N. Apoptosis in Ish-PCMV-MGLL cells after transfected with si\u003cem\u003eAKR1C1\u003c/em\u003e or siNC with 30μM MPA for 48h by flow cytometry assay.\u003c/p\u003e\u003cp\u003eAll experiments were repeated three times at least. *\u003cem\u003eP\u003c/em\u003e\u0026lt; 0.05, **\u003cem\u003eP\u003c/em\u003e\u0026lt; 0.01, ***\u003cem\u003eP\u003c/em\u003e\u0026lt; 0.001 and ****\u003cem\u003eP\u003c/em\u003e\u0026lt;0.0001 for statistical analysis of the indicated groups.\u0026nbsp;\u003c/p\u003e","description":"","filename":"Figure6.jpg","url":"https://assets-eu.researchsquare.com/files/rs-1745135/v1/51d44c2b2f8452c9d05045bd.jpg"},{"id":23344251,"identity":"1cff9da9-d85d-4e90-a705-c920620d56bc","added_by":"auto","created_at":"2022-07-01 19:58:54","extension":"jpg","order_by":7,"title":"Figure 7","display":"","copyAsset":false,"role":"figure","size":1643298,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eABX-1431 enhances the sensitivity of EAC to progesterone by inhibiting MGLL in vivo and vitro.\u003c/strong\u003e\u003c/p\u003e\u003cp\u003e7A. Expression of MGLL in IshMR cells treated with different concentration of ABX.\u003c/p\u003e\u003cp\u003e7B. MTT assay showed the inhibition rate of IshMR cells treated with different concentrations of ABX and the IC50 of ABX on IshMR cells\u003c/p\u003e\u003cp\u003e7C. The effects of MPA and ABX treatment on cell viability by the CCK8 assay.\u003c/p\u003e\u003cp\u003e7D. The proliferation rate of IshMR treated with MPA or/and ABX by EDU assay.\u003c/p\u003e\u003cp\u003e7E. The colony-forming ability of IshMR treated with MPA or/and ABX.\u003c/p\u003e\u003cp\u003e7F. The apoptosis of IshMR cells treated with MPA or/and ABX by flow cytometry. \u003c/p\u003e\u003cp\u003e7G. Images of tumors of IshMR cells with MPA, ABX and combined drug. And the volume and weight of tumor and the body weight of the four groups of mice.\u003c/p\u003e\u003cp\u003e7H. Representative images of IHC staining of MGLL, cleaved-caspase-3 and Ki-67 in tumor\u0026nbsp;tissues.\u0026nbsp;Scale bar:10μm.\u003c/p\u003e\u003cp\u003eAll experiments were repeated three times at least. *\u003cem\u003eP\u003c/em\u003e\u0026lt; 0.05, **\u003cem\u003eP\u003c/em\u003e\u0026lt; 0.01, ***\u003cem\u003eP\u003c/em\u003e\u0026lt; 0.001 and ****\u003cem\u003eP\u003c/em\u003e\u0026lt;0.001 for statistical analysis of the indicated groups. \u003c/p\u003e\u003cp\u003e\u003cbr\u003e\u003c/p\u003e","description":"","filename":"Figure7.jpg","url":"https://assets-eu.researchsquare.com/files/rs-1745135/v1/4b5d77e8d3341df31f583c5e.jpg"},{"id":30703013,"identity":"5c02e4ad-38d0-4d6a-86db-4555557cc3ab","added_by":"auto","created_at":"2022-12-23 08:10:02","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1250991,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-1745135/v1/d718a83b-e957-4061-b457-6a986bb31dc9.pdf"},{"id":23343944,"identity":"47eb2462-53ba-4724-a53b-f370773287cb","added_by":"auto","created_at":"2022-07-01 19:53:54","extension":"docx","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":802142,"visible":true,"origin":"","legend":"","description":"","filename":"WesternBlotoriginaldata.docx","url":"https://assets-eu.researchsquare.com/files/rs-1745135/v1/d5a00a955b4a1efbfa282df3.docx"}],"financialInterests":"(Not answered)","formattedTitle":"ABX-1431 inhibits the development of endometrial adenocarcinoma and reverses progesterone resistance by regulating the MGLL-ROS/AKR1C1 pathway","fulltext":[{"header":"Introduction","content":"\u003cp\u003eEndometrial carcinoma (EC) is one of the most common gynaecologic malignant tumors, ranking in 4th and 6th place of all cancers with respect to morbidity and mortality, respectively\u003csup\u003e\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e\u003c/sup\u003e. Endometrioid adenocarcinoma (EAC) is mainly associated with obesity, hypertension and other factors, about 5% of patients with EAC develop the disease before the age of 40, but in recent years, statistics have found that the proportion of patients with the disease before the age of 40 has increased to 10%, these patients are normally inclined to select progesterone-based therapy. Studies revealed that approximately 55% of EAC patients showed a complete response to conservative treatment that included medroxy-progesterone acetate (MPA), with a 47% recurrence rate\u003csup\u003e\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e\u003c/sup\u003e. Nevertheless, other studies have shown that more than 30% of EAC patients do not respond to MPA and acquired resistance to progesterone during the treatment\u003csup\u003e\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e\u003c/sup\u003e. In consequence, progesterone resistance has become an urgent clinical problem to be solved. In this study, we deeply explored the molecular mechanism of progesterone resistance in EAC, hoping to improve progesterone resistance and poor prognosis of it.\u003c/p\u003e \u003cp\u003eMonoacylglycerol lipase (MGLL, also MAGL) is an enzyme belonging to the family of serine hydrolases that preferentially catalyzes the hydrolysis of mono-triglycerides to glycerol and fatty acids and specializes in the degradation of endocannabinoids to the major enzymes responsible for controlling and regulating the levels of this cannabinoid\u003csup\u003e\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e, \u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e\u003c/sup\u003e. It has become more and more important as an integrated metabolic hub, which not only controls the level of 2-arachidonoylglycerol(2-AG), but also controls the level of other monoacylglycerides. In addition, it controls the free fatty acids produced by their hydrolysis as well as other levels with proinflammatory or tumorigenic effects from the further metabolism of fatty acids. Accumulating evidence suggests that MGLL promotes tumor invasion and metastasis by up-regulating tumorigenic signals\u003csup\u003e\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e\u003c/sup\u003e. In cancer cells, MGLL hydrolyzes monoacylglycerols into free fatty acids, maintains elevated levels of these molecules, and further converts them into different tumorigenic lipids such as lysophosphatidic acid (LPA), prostaglandin E2(PGE2)\u003csup\u003e\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e, \u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e\u003c/sup\u003e. It is well-known that EAC is a malignant tumor associated with abnormal lipid metabolism, and MGLL may play an important role in it, our group found that MGLL was overexpressed in progesterone resistance cells compared to sensitivity cells in previous studies. However, the function of MGLL in EAC and progesterone resistance.\u003c/p\u003e \u003cp\u003eABX-1431 is an efficient inhibitor of MGLL which is identified and developed by Cisar et al\u003csup\u003e\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e\u003c/sup\u003e. Studies have shown that ABX-1431 inhibit MGLL obviously with dose-dependent in vitro. At present, ABX-1431 has positive clinical results\u003csup\u003e\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e, \u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e\u003c/sup\u003e, and MGLL inhibitors have good prospects for application in a variety of human diseases. However, there is no researches associated with ABX-1431 in EAC.\u003c/p\u003e \u003cp\u003eIn the present study, we explored the function and mechanism of MGLL in the development of EAC and progesterone resistance by carrying out a range of experiments \u003cem\u003ein vivo\u003c/em\u003e and in \u003cem\u003evitro\u003c/em\u003e. Meanwhile, we investigated the efficacy of ABX-1431 for reversing progesterone resistance so as to provide efficient treatment for clinic in EAC.\u003c/p\u003e"},{"header":"Results","content":"\u003cdiv class=\"Section2\" id=\"Sec3\"\u003e\n \u003ch2\u003eMGLL is a key gene high expressed in EAC and correlated to the progesterone resistance\u003c/h2\u003e\n \u003cp\u003eWe analyzed the microarray data of EAC progesterone-sensitive cell line(Ishikawa) and the EAC progesterone-resistant cell line(IshikawaMR), and the raw data arising from this analysis has been uploaded to the GEO database (reference: GSE121367). The threshold of differential genes was set at a adj.P\u0026thinsp;\u0026lt;\u0026thinsp;0.005 and | fold change (FC)|\u0026ge;3, a heat map was created to show the differentially expressed genes (Fig. \u003cspan class=\"InternalRef\"\u003e1\u003c/span\u003eA). We found that the mRNA expression of MGLL in the IshMR cell line was higher than that in the Ish cell line (Fig. \u003cspan class=\"InternalRef\"\u003e1\u003c/span\u003eB, C). Subsequently, we performed Western Blot and found that the expression of MGLL in IshMR cell line increased compared with Ish cell line (Fig. \u003cspan class=\"InternalRef\"\u003e1\u003c/span\u003eD). We collected clinical specimens of endometrial adenocarcinoma/atypical hyperplasia from patients who treated with conservative progesterone for IHC experiments. According to clinical outcomes, the species were divided into 3 groups: complete response (CR), partial response (PR) and no response/progression disease (NC/PD). The staining of clinical specimens in the 3 groups before and after treatment showed that MGLL was expressed at low levels in the CR and PR group and there was no statistical difference before and after treatment. Furthermore, the expression of MGLL in the NC/PD group was significantly higher after treatment (Fig. \u003cspan class=\"InternalRef\"\u003e1\u003c/span\u003eE).\u003c/p\u003e\n \u003cp\u003eTo detect whether MGLL expression altered in EAC development, we further analyzed the data of GSE183185, a matched EAC and adjacent data in GEO database, and the results showed that MGLL expression was significantly higher in tumors compared with adjacent tissues (Fig. \u003cspan class=\"InternalRef\"\u003e1\u003c/span\u003eF). To verify the results from database, we analyzed MGLL mRNA level in 16 EAC/adjacent tissues, and the expression of MGLL was remarkedly up-regulated in EAC tissues compared to adjacent tissues (Fig. \u003cspan class=\"InternalRef\"\u003e1\u003c/span\u003eG). These findings were consistent with those from clinical samples (Fig. \u003cspan class=\"InternalRef\"\u003e1\u003c/span\u003eH).\u003c/p\u003e\n \u003cp\u003eIn summary, MGLL is a key gene high expressed in EAC and correlated to the progesterone resistance.\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv class=\"Section2\" id=\"Sec4\"\u003e\n \u003ch2\u003eMGLL promotes the proliferation and inhibits the apoptosis of EAC cells\u003c/h2\u003e\n \u003cp\u003eWe detected the expression of MGLL in 5 EAC cell lines and found that MGLL was barely expressed in AN3CA cells and abundant expressed in HEC-1A(Fig. \u003cspan class=\"InternalRef\"\u003e2\u003c/span\u003eA). Thus, we chose AN3CA and HEC-1A cell line to create MGLL overexpression model and knocked-out model respectively. Western Blot and RT-PCR confirmed successful overexpression and knock-down of MGLL (Fig. \u003cspan class=\"InternalRef\"\u003e2\u003c/span\u003eB, C). Overexpression of MGLL in AN3CA cell promoted the proliferation through MTT, EDU and colony formation assays, while the ability was significantly inhibited upon knock-down of MGLL in HEC-1A cell line (Fig. \u003cspan class=\"InternalRef\"\u003e2\u003c/span\u003eD, E, F). Flow cytometry assay was used to detect whether the expression of MGLL could affect apoptosis of EAC cells. The results showed that the proportion of apoptotic cells decreased in AN3CA cells with MGLL overexpression and knock-down of MGLL caused significant apoptosis of HEC-1A cells (Fig. \u003cspan class=\"InternalRef\"\u003e2\u003c/span\u003eG). Then we performed Western Blot assay to detect the expression of proteins involved in cell cycle and apoptosis. Consistent with above assays, proliferation-related proteins including CyclinD1, CDK4 and anti-apoptotic protein Bcl2 were significantly higher in overexpressing MGLL cells, and pro-apoptotic protein such as cleaved-PARP and cleaced-caspase3 were increased in knock-down MGLL cells (Fig. \u003cspan class=\"InternalRef\"\u003e2\u003c/span\u003eH). The results suggested that upregulation of MGLL promoted the proliferation and inhibited apoptosis of EAC cells.\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv class=\"Section2\" id=\"Sec5\"\u003e\n \u003ch2\u003eMGLL enhances the invasion and migration of EAC cells\u003c/h2\u003e\n \u003cp\u003eWe further investigated whether MGLL affected metastasis of EAC cells. Transwell assay showed the invasion and migration abilities of AN3CA cells in MGLL overexpression group were significantly enhanced compared to the control group, and the abilities of HEC-1A cells in MGLL knock-down group were obviously suppressed (Fig. \u003cspan class=\"InternalRef\"\u003e3\u003c/span\u003eA). As shown in Fig. \u003cspan class=\"InternalRef\"\u003e3\u003c/span\u003eB, compared with AN3CA-PCMV-Ctrl cells, the migration speed of AN3CA-PCMV-MGLL cells was remarkedly faster, and that of HEC-1A-shMGLL cells was significantly slower than that of HEC-1A-shCtrl cells (Fig. \u003cspan class=\"InternalRef\"\u003e3\u003c/span\u003eB). Epithelial mesenchymal transformation pathway (EMT) represents the change of cell metastasis ability, and the decrease of epithelial-related markers such as E-cadherin, \u0026beta;-catenin and ZO-1 indicate the activation of EMT pathway and the enhancement of cell metastasis ability\u003csup\u003e\u003cspan class=\"CitationRef\"\u003e12\u003c/span\u003e\u003c/sup\u003e. Therefore, we tested the expression of related markers and found that epithelial-related markers were lower in AN3CA-PCMV-MGLL cell than AN3CA-PCMV-Ctrl cell and higher in HEC-1A-shMGLL than HEC-1A-shCtrl (Fig. \u003cspan class=\"InternalRef\"\u003e3\u003c/span\u003eC). It indicated that MGLL could promote the migration and invasion of endometrioid adenocarcinoma cells.\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv class=\"Section2\" id=\"Sec6\"\u003e\n \u003ch2\u003eMGLL overexpression conteracts the sensitivity of EAC cells to progesterone\u003c/h2\u003e\n \u003cp\u003eWe established Ish cells with MGLL overexpression using lentivirus and detected by Western blot and RT-PCR at the protein and mRNA levels (Fig. \u003cspan class=\"InternalRef\"\u003e4\u003c/span\u003eA, B). MTT assays showed that the IC\u003csub\u003e50\u003c/sub\u003e of the Ish-PCMV-MGLL cells almost increased 3-fold compared with Ish-PCMV-Ctrl cells, after 48-hours of treatment with different concentrations of MPA. Ish-PCMV-MGLL cells exhibited a stronger viability at the same concentration of MPA (Fig. \u003cspan class=\"InternalRef\"\u003e4\u003c/span\u003eC). The proliferation ability of Ish-PCMV-MGLL and Ish-PCMV-Ctrl cells treated with MPA at concentrations of 0 and 60\u0026micro;M for 48 h was detected by EDU assay. The results showed that the proliferation ability of Ish-PCMV-MGLL was increased (Fig. \u003cspan class=\"InternalRef\"\u003e4\u003c/span\u003eD). Furthermore, the percentage of apoptotic cells was lower in the Ish-PCMV-MGLL group than in the Ish-PCMV-Ctrl after MPA treatment by flow cytometry (Fig. \u003cspan class=\"InternalRef\"\u003e4\u003c/span\u003eE). Western blot was then carried out to detect the expression of proteins related to proliferation and apoptosis. Following MPA treatment, when compared with the Ish-PCMV- Ctrl group, the expression levels of CDK4, CyclinD1, and Bcl2, in the Ish-PCMV- MGLL group were significantly up-regulated while the expression of cleaved-PARP was significantly down-regulated (Fig. \u003cspan class=\"InternalRef\"\u003e4\u003c/span\u003eF). We also detected the migration and invasion of cells in response to MPA through transwell assay, and the ability of Ish-PCMV-MGLL was significantly higher than that of the control group (Fig. \u003cspan class=\"InternalRef\"\u003e4\u003c/span\u003eG). Subsequently, we established nude-mouse xenograft tumor models using Ish-PCMV-MGLL and Ish-PCMV-Ctrl cells. Results showed that MPA treatment showed unconspicuous inhibitory effect on the Ish-PCMV-MGLL tumors. However, in the Ish-PCMV-Ctrl group, MPA treatment significantly inhibit tumor growth (Fig. \u003cspan class=\"InternalRef\"\u003e4\u003c/span\u003eG).\u003c/p\u003e\n \u003cp\u003eIn conclusion, the overexpression of MGLL was related to the occurrence and development of progesterone resistance in EAC.\u003c/p\u003e\n\u003c/div\u003e\n\u003cdiv class=\"Section2\" id=\"Sec7\"\u003e\n \u003ch2\u003eMGLL knockdown renders EAC cells more sensitive to progesterone\u003c/h2\u003e\n \u003cp\u003eWe established IshMR-shMGLL cells by lentivirus transfection and investigated expression levels by Western blot and RT-PCR (Fig. \u003cspan class=\"InternalRef\"\u003e5\u003c/span\u003eA, B). MTT assays showed that the survival rates of IshMR-shMGLL cells after 48-hours of treatment with different concentrations of MPA were lower significantly than those of the shCtrl group (Fig. \u003cspan class=\"InternalRef\"\u003e5\u003c/span\u003eC). EDU assays showed that the DNA synthesis of IshMR-shMGLL cells declined sharply when treated with 0, 90\u0026micro;M of MPA compared with the control group (Fig. \u003cspan class=\"InternalRef\"\u003e5\u003c/span\u003eD). Flow cytometry further revealed that the proportion of cells showing signs of apoptosis was significantly higher in IshMR-shMGLL group(Fig. \u003cspan class=\"InternalRef\"\u003e5\u003c/span\u003eE). The detection of proteins related to proliferation and apoptosis further confirmed these experimental findings (Fig. \u003cspan class=\"InternalRef\"\u003e5\u003c/span\u003eF). Transwell assays were performed to examine the migration and invasion ability of cells in response to MPA, and the capacity of IshMR-shMGLL was inhibited (Fig. \u003cspan class=\"InternalRef\"\u003e5\u003c/span\u003eG). IshMR-shMGLL and IshMR-shCtrl nude-mouse xenograft tumor models were established and then treated with MPA. These experiments revealed that the IshMR-shMGLL group exhibited a greater extent of tumor shrinkage, while the IshMR-shCtrl group only exhibited a slight amount of shrinkage (Fig. \u003cspan class=\"InternalRef\"\u003e5\u003c/span\u003eH).\u003c/p\u003e\n \u003cp\u003eIn summary, the suppression of MGLL in progesterone-resistant cells enhanced the sensitivity of cells to progesterone and reversed progesterone resistance.\u003c/p\u003e\n \u003cp\u003eMGLL regulates AKR1C1 by mediating the generation of ROS to induce the progesterone resistance in EAC\u003c/p\u003e\n \u003cp\u003eTo further explore the mechanism underlying the effect of MGLL on biological function and progesterone resistance in EAC, we performed next-generation sequence (NGS) in IshMR-shMGLL and IshMR-shCtrl cells. We did Gene Ontology (GO) enrichment analyses for the altered gene and found that MGLL plays important roles in protein binding, membrane composition and so on (Fig. \u003cspan class=\"InternalRef\"\u003e6\u003c/span\u003eA). Differential genes (DEG) threshold was set at a adj.P\u0026thinsp;\u0026lt;\u0026thinsp;0.005 and |fold change(FC) |\u0026ge;3. A volcano plot was created to show the differentially expressed genes. A heat map was also created to show the distribution of differentially expressed genes between two groups. From the graph, we found that MGLL might regulate AKR1C1(Fig. \u003cspan class=\"InternalRef\"\u003e6\u003c/span\u003eB, C). We further confirmed the relationship between MGLL and AKR1C1 using The Cancer Genome Atlas (TCGA) database of EC (Fig. \u003cspan class=\"InternalRef\"\u003e6\u003c/span\u003eD) and found that AKR1C1 was highly expressed in IshMR cell(Fig. \u003cspan class=\"InternalRef\"\u003e6\u003c/span\u003eE). GSEA analysis indicated that MGLL was able to lead to alterations of hypoxic microenvironment within tumor cells (Fig. \u003cspan class=\"InternalRef\"\u003e6\u003c/span\u003eF, G), and subsequently we found that MGLL led to an increase in ROS generation (Fig. \u003cspan class=\"InternalRef\"\u003e6\u003c/span\u003eH). It has been documented that an increasing level of ROS could induce AKR1C1 expression. So we examined the effect of ROS on AKR1C1 (Fig. \u003cspan class=\"InternalRef\"\u003e6\u003c/span\u003eI and Fig. \u003cspan class=\"InternalRef\"\u003e6\u003c/span\u003eJ) and verified that MGLL regulated AKR1C1 expression by CO-IP assay (Fig. \u003cspan class=\"InternalRef\"\u003e6\u003c/span\u003eK). The above results demonstrated that MGLL regulated the expression of AKR1C1 by promoting the generation of ROS.\u003c/p\u003e\n \u003cp\u003eTo validate the above conclusions, we knocked down AKR1C1 in Ish-PCMV-MGLL cells by siRNA and then carried out rescue experiments to detect the sensitivity to MPA. The knockdown efficiency of AKR1C1 was verified by Western Blot assay (Fig. \u003cspan class=\"InternalRef\"\u003e6\u003c/span\u003eL). The results of MTT assay and apoptosis assay showed that interfering with AKR1C1 in Ish-PCMV-MGLL cells restored the sensitivity to MPA (Fig. \u003cspan class=\"InternalRef\"\u003e6\u003c/span\u003eM, N).\u003c/p\u003e\n \u003cp\u003eTo draw a conclusion, MGLL is involved in progesterone resistance in EAC by promoting the expression of AKR1C1.\u003c/p\u003e\n \u003ch2\u003eABX-1431 inhibited the growth of EAC and reversed progesterone resistance \u003cspan class=\"BoldItalic\" name=\"Emphasis\" type=\"BoldItalic\"\u003ein vitro\u003c/span\u003e by inhibiting the expression of MGLL\u003c/h2\u003e\n \u003cp\u003eGiven that MGLL plays an important role in progesterone resistance, it is bold to hypothesize that targeted inhibition of MGLL by ABX-1431 may have significant therapeutic advantages. As shown in Fig. \u003cspan class=\"InternalRef\"\u003e7\u003c/span\u003eA, ABX-1431 could inhibit the expression of MGLL, and the inhibitory effect became stronger with the increase of concentration and extension of time. We determined that the IC50 of ABX-1431 on IshMR cells was 27.35\u0026micro;M by MTT assay (Fig. \u003cspan class=\"InternalRef\"\u003e7\u003c/span\u003eB). Then we tested the effect of ABX-1431 and MPA on the viability of IshMR cells through CCK8, and found that 30\u0026micro;M MPA alone had no significant inhibitory effect on the viability of IshMR cells, while 20\u0026micro;M ABX-1431 could significantly inhibit the viability of EAC cells. Moreover, treatment with ABX-1431 combined with MPA further reduced cell viability (Fig. \u003cspan class=\"InternalRef\"\u003e7\u003c/span\u003eC). EDU was applied to detect the ratio of proliferating cells and showed that combination of treatment remarkedly inhibited proliferation (Fig. \u003cspan class=\"InternalRef\"\u003e7\u003c/span\u003eD). The long-term effects of two drugs on the proliferation ability of progestin-resistant cells were determined by colony formation assay, and the results were consistent with MTT (Fig. \u003cspan class=\"InternalRef\"\u003e7\u003c/span\u003eE). Apoptosis assay demonstrated that the combination of ABX-1431 and MPA for 48 hours, significantly promoted apoptosis compared with the control, MPA and ABX-1431 groups (Fig. \u003cspan class=\"InternalRef\"\u003e7\u003c/span\u003eF). Together, these data suggested that ABX-1431 increased the sensitivity of EAC cells to progesterone.\u003c/p\u003e\n \u003ch2\u003eCo-treatment with ABX-1431 and MPA synergistically inhibited the proliferation of progesterone-resistant EAC \u003cspan class=\"BoldItalic\" name=\"Emphasis\" type=\"BoldItalic\"\u003ein vivo\u003c/span\u003e\u003c/h2\u003e\n \u003cp\u003eIn order to further verify the sensitizing effect of ABX-1431 on progesterone, IshMR cell xenograft models were established and treated with DMSO, MPA and/or ABX-1431, respectively. It was found that the combination of MPA and ABX-1431 significantly inhibited the growth of tumors compared with the control group and single drug group, and there was no significant difference in the body weight of mice among the four groups (Fig.\u0026nbsp;\u003cspan class=\"InternalRef\"\u003e7\u003c/span\u003eG). Consequently, we detected markers associated with cell proliferation and apoptosis through IHC assay and validated the same results (Fig.\u0026nbsp;\u003cspan class=\"InternalRef\"\u003e7\u003c/span\u003eH). It can be seen that in vivo, ABX-1431 was able to enhance the sensitivity of EAC to progesterone and inhibit the growth of tumors.\u003c/p\u003e\n\u003c/div\u003e"},{"header":"Discussion","content":"\u003cp\u003eIn recent years, with the increasing incidence of endometrial adenocarcinoma (EAC) and the younger patients, more and more population tend to choose conservative treatment to preserve reproductive function. However, progesterone resistance is a difficult problem in the treatment of EAC. Many theories are related to progesterone resistance, such as PGR-ER imbalance theory and abnormal activation of multiple signaling pathway including PI3K-AKT, Nrf2-survivin and autophagy pathway\u003csup\u003e\u003cspan additionalcitationids=\"CR14\" citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e\u003c/sup\u003e, but the specific molecular mechanism of progesterone resistance is still unclear. When progesterone resistance occurs in tumors, progestin can\u0026rsquo;t exert its anticancer effects, but shows the function of promoting cancer cell proliferation and metastasis. Therefore, it is urgent to explore the molecular mechanism related to progestogen resistance in order to reverse progestogen resistance, improve the prognosis of patients and preserve the reproductive function of young patients.\u003c/p\u003e \u003cp\u003eIn consideration of the problem, our group previously established progesterone resistance cell line based on Ishikawa cell and performed NGS in progesterone sensitivity cell (Ishikawa) and progesterone resistance cell (IshMR)\u003csup\u003e\u003cspan citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e\u003c/sup\u003e. In this study, we firstly analyzed the RNA-seq results of Ishikawa cell and IshMR cell and screened out that MGLL expression was significantly increased in progesterone resistant cell lines\u003csup\u003e\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e\u003c/sup\u003e. MGLL is a key hub in the lipid signaling network and has been found to be involved in the development of varieties of tumor, such as breast cancer and melanoma cancer \u003csup\u003e\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e, \u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e\u003c/sup\u003e. Subsequently, we confirmed that the expression of MGLL was elevated in EAC through the analysis of paired sample data of EAC in GEO database and the detection of tumors and adjacent tissues of EAC patients in Qilu Hospital of Shandong University. Meanwhile, we further verified that MGLL expression was obviously increased in progesterone resistance cell line and samples. Therefore, we hypothesized that MGLL was highly expressed in EAC and has a correlation with progesterone resistance.\u003c/p\u003e \u003cp\u003eSubsequently, we overexpressed and knocked down MGLL in EAC cell lines, respectively and conducted functional experiments \u003cem\u003ein vivo and in vitro\u003c/em\u003e.We verified that MGLL could promote the proliferation and inhibit apoptosis of tumor cells. It has been confirmed in the literature that the expression of MGLL in the primary lesion is higher in deeper areas of the tumor, indicating that tumor cells overexpressing MGLL are more aggressive\u003csup\u003e\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e\u003c/sup\u003e. So we also focused on the metastatic ability of cells with different expression levels of MGLL and verified it. Moreover, several studies have shown that MGLL is able to act by regulating the EMT pathway\u003csup\u003e\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e, \u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e\u003c/sup\u003e, so we verified that MGLL promoted the metastasis of EAC cells by regulating the EMT pathway.\u003c/p\u003e \u003cp\u003eIn order to determine whether MGLL plays an important role in progesterone resistance of EAC, we conducted functional studies by overexpressing and knocking down of MGLL in EAC progesterone-sensitive cell lines and progesterone-resistant cell lines, respectively. The results showed that MGLL significantly improved the viability of Ish cells treated with MPA and induced progesterone resistance. In contrast, knocked down MGLL inhibited the proliferative capacity of IshMR cells, making them sensitive to progesterone. The results in vivo were consistent with those in vitro. These results indicated that the different expression levels of MGLL in tumors could affect the sensitivity of EAC cells to progesterone. Therefore, we believed that MGLL can promote the progress of EAC and participate in the development of progesterone resistance in EAC.\u003c/p\u003e \u003cp\u003eThen, we performed NGS in IshMR-shMGLL cells and control cells and found that AKR1C1 expression was significantly reduced in IshMR-shMGLL cells. The location of two genes in the heatmap suggested that MGLL may regulate AKR1C1. GSEA enrichment analysis showed that overexpression of MGLL resulted in the development of hypoxia in the tumor microenvironment. At present, it is generally believed that the contradiction between the rapid growth of tumor tissue and the incomplete vascular system in tumor tissue leads to insufficient oxygen supply in tumor tissue, presenting a hypoxia microenvironment\u003csup\u003e\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e\u003c/sup\u003e. Tumor cells metabolize energy through anaerobic glycolysis, resulting in the accumulation of lactic acid and increased production of reactive oxygen species. Tumor cells in hypoxia microenvironment can escape drugs targeted at cell division by producing ROS and lead the resistance\u003csup\u003e\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e, \u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e\u003c/sup\u003e.So we further examined the effect of MGLL on ROS generation and found that MGLL overexpression could lead to increased generation of ROS in EAC cells. Several literatures have demonstrated that ROS can induce the expression of AKR1C1\u003csup\u003e24\u0026ndash;26\u003c/sup\u003e, and our experiments obtained the same results in EAC. The aldosterone reductase superfamily(AKRs) is a nicotinamide adenine dinucleotide phosphate (NADPH) -dependent oxidoreductase, and previous studies have shown that AKR1C1 can degrade progesterone into metabolite 20α-DHP, which binds to the specific plasma membrane and affects mitosis and cytoskeletal formation\u003csup\u003e\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e 28\u003c/sup\u003e. Overexpression of AKR1C1 may lead to inhibiting the production of progesterone receptors(PGR) and affect progesterone action\u003csup\u003e\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e\u003c/sup\u003e. Therefore, we speculated that MGLL promotes the expression of AKR1C1 by regulating the generation of ROS in EAC cells and accelerates the degradation of progesterone, leading to the development of progesterone resistance. To test the hypothesis, we interfered with AKR1C1 expression in cells overexpressing MGLL and found that no progesterone-resistant effect occurred in the cells. The above results demonstrated that MGLL is involved in progestogen resistance in EAC by activating AKR1C1.\u003c/p\u003e \u003cp\u003eFinally, in order to explore efficient strategies to reserve progesterone resistance in EAC, we selected MGLL inhibitor for experiments according to previous researches. ABX-1431 is a lead compound for clinical evaluation based on optimized activity and selectivity for multiple human protein tissues\u003csup\u003e\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e\u003c/sup\u003e. Currently, ABX-1431 has successfully completed phase I clinical trials showing that the compound is well tolerated and safe, and phase II clinical studies of ABX-1431 are ongoing\u003csup\u003e\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e\u003c/sup\u003e. Therefore, we selected ABX-1431 as a MGLL inhibitor to verify whether it could inhibit the proliferation of EAC and reverse progesterone resistance. MTT, EDU, clony formation and apoptosis assays proved that the application of ABX-1431 could not only inhibit the proliferation and promote apoptosis of EAC cells, but also sensitize the effect of progesterone. Therefore, we believed that the combination of ABX-1431 and progesterone could be used in clinical treatment to improve the sensitivity and efficacy of EAC patients treated conservatively with progesterone.\u003c/p\u003e \u003cp\u003eIn summary, it is the first study to confirm that MGLL is one of the key moleculars involved in the development of EAC and progesterone resistance.It acts by affecting the hypoxia microenvironment in tumor cells and then regulating the expression of AKR1C1. We hypothesize that the high expression level of MGLL could be considered as a standard biomarker to evaluate the efficacy of progesterone in EAC patients. Our data also demonstrate that application of ABX-1431, an inhibitor of MGLL, can reverse progesterone resistance in patients with EAC and can be expected to achieve targeted therapy. Combination of ABX-1431 and progesterone can reserve progesterone resistance effectively and may provide new therapeutic strategies for clinical practice.\u003c/p\u003e"},{"header":"Materials And Methods","content":"\u003cdiv id=\"Sec10\" class=\"Section2\"\u003e \u003ch2\u003eCell lines and cell culture\u003c/h2\u003e \u003cp\u003eIshikawa cells (referred to throughout this paper as \u0026lsquo;Ish\u0026rsquo;), AN3CA, RL-95-2, HEC-1A and KLE cells were purchased from Shanghai Zhong Qiao Xin Zhou Biotechnology Co. Progesterone resistant cells which we referred to as IshikawaMR (or \u0026lsquo;IshMR\u0026rsquo;) were previously obtained by our group via the increasing MPA concentration gradient method\u003csup\u003e\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e\u003c/sup\u003e. Ish and IshMR cells were cultured in RPMI1640 medium (BI, USA) containing 10% fetal bovine serum (BI, USA), RL-95-2 and HEC-1A cells were routinely grown in M5A media, AN3CA cells were cultured in RPMI-DMEM medium (BI, USA), and all cell lines were cultured at 37\u0026deg;C in a 5% CO\u003csub\u003e2\u003c/sub\u003e humidified atmosphere. 10\u0026micro;M MPA was added to the medium containing the IshMR cells to maintain resistance.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec11\" class=\"Section2\"\u003e \u003ch2\u003eWestern blot analysis\u003c/h2\u003e \u003cp\u003eCells were collected, lysed using a mixture containing RIPA, PMSF, and NaF, and the supernatant was taken after centrifugation and sonication to determine the protein concentration using the BCA method (Tiangen Biotech Co., Ltd., Beijing, China). Protein was separated by SDS-PAGE and transferred to PVDF membranes (Millipore, Bedford, MA, USA). The band was cropped according to the weight of the target gene and placed in the antibody overnight, and placed in the secondary antibody for 2h at room temperature. Protein bands were detected by ImageQuant LAS4000 (General Electric Company, Boston, MA, USA) and quantified by ImageJ software. β-actin was detected as a loading control.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec12\" class=\"Section2\"\u003e \u003ch2\u003eQuantitative real‑time transcription‑polymerase chain reaction(qRT-PCR)\u003c/h2\u003e \u003cp\u003eTotal RNA was extracted from cells or tissues and the concentration and purity was evaluated with a spectrophotometer (Thermo Fisher Scientific Inc., MA, USA). RNA was then reverse transcribed into cDNA (3000 ng/10\u0026micro;l reaction system). PCR reactions were then performed on a StepOne \u0026trade; PCR amplifier (Applied Biosystems, USA) with SYBR-green (TAKARA, Japan) in a 10\u0026micro;l reaction system; β-actin was used as a control. The primers used are shown in the Supplementary information (Supplement Table\u0026nbsp;1).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec13\" class=\"Section2\"\u003e \u003ch2\u003eTissue samples and immunohistochemistry assays(IHC)\u003c/h2\u003e \u003cp\u003eThe EAC and adjacent tissues for Western Blot, RT-qPCR and IHC were from patients with primary EAC without previous therapy from Qilu Hospital of Shandong University. We acquired tissues from 37 patients who underwent progesterone treatment at Qilu Hospital of Shandong University between 2010 and 2020. The tissues were collected from the Pathology Department at Qilu Hospital. These patients did not have any other diseases of the reproductive system. The pathological diagnosis of endometrial carcinoma or hyperplasia was made in accordance with the latest National Comprehensive Cancer Network (NCCN) guidelines. All patients received medroxyprogesterone acetate for at least 6 months and were followed up regularly. Complete response (CR) was defined as the absence of residual hyperplasia or cancer in more than 95% of the tissue. Partial response (PR) was defined as \u0026lt;\u0026thinsp;50% of residual hyperplastic glands. If more than 50% of residual hyperplasia was evident, and the extent of hyperplasia was similar to or worse than before progesterone treatment, then the patients were classified as no change(NC) or progressive disease (PD) \u003csup\u003e\u003cspan additionalcitationids=\"CR32\" citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eAll human tissue samples were dehydrated for 1h and dewaxed with xylene and ethyl alcohol. We then used a microwave antigen retrieval technique to repair antigen. We then stained the tissues antibodies against MGLL (1:300), ki67(1:500) and cleaved-casepase3(1:800). Positive staining was subsequently visualized with 3,3\u0026rsquo;-Diaminobenzidine (DAB) and counterstained with hematoxylin Detailed experimental and analytical methods for IHC were described previously\u003csup\u003e\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec14\" class=\"Section2\"\u003e \u003ch2\u003eAntibodies and agents\u003c/h2\u003e \u003cp\u003eAntibodies used in WB and IHC experiments were following: MGLL (Abcam, ab234701), CDK4 (Cell Signaling Technologies, #12790), Cyclin D1 (Cell Signaling Technologies, #2978), cleaved-PARP (Cell Signaling Technologies, #5625), Bcl2 (Cell Signaling Technologies, #4223), cleaved-casepase3 (Cell Signaling Technologies, #9664), EMT kit(Cell Signaling Technologies, #9782), β-actin (Cell Signaling Technologies, #4970), Ki67 (Abcam, ab92742),AKR1C1(Abcam,ab179448), mouse IgG (Cell Signaling Technologies, #7076), and rabbit IgG (Cell Signaling Technologies, #7074).Antibodies for Co-IP was MGLL(Proteintech,14985-1-AP) and AKR1C1(Abcam,ab179448).Medroxyprogesterone acetate(MPA) and ABX-1431 were obtained from Abcam and Selleck, respectively, and were both diluted in DMSO.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec15\" class=\"Section2\"\u003e \u003ch2\u003eCCK8 assays\u003c/h2\u003e \u003cp\u003e0.3 \u0026times; 10\u003csup\u003e4\u003c/sup\u003e cells were seeded into 96-well plates, and 10 \u0026micro;lCCK8 was added to each well after cell attachment, and OD550 absorbance was measured 1h later, as the first day, and then at the same time every day.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec16\" class=\"Section2\"\u003e \u003ch2\u003eMTT assays\u003c/h2\u003e \u003cp\u003eMTT assays were used to analyze cell viability and determine the 50% inhibitory concentration (IC\u003csub\u003e50\u003c/sub\u003e); 0.3 \u0026times; 10\u003csup\u003e4\u003c/sup\u003e cells were seeded into a 96-well plate, and different concentrations of MPA were added to it the next day. After culture for 48 h, 10\u0026micro;l MTT (5mg/mL in PBS) solution was added to each well, as if it had been incubated in an incubator for 4 h. Formazan crystals were dissolved in 150\u0026micro;l of dimethylsulfoxide (DMSO; Sigma-Aldrich, St Louis, MO, USA). The absorbance at OD550 was measured, and the inhibition rate of the drug on the cells was calculated.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec17\" class=\"Section2\"\u003e \u003ch2\u003eColony formation assay\u003c/h2\u003e \u003cp\u003e600 cells were seeded into 6-well plates, attached or treated with MPA, and cultured for about 5\u0026ndash;14 days when the cell density was appropriate, the cells were fixed with methanol and stained with crystal violet (Beyotime, Beijing, China). Photographs were taken for statistics.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec18\" class=\"Section2\"\u003e \u003ch2\u003eEDU incorporation assays\u003c/h2\u003e \u003cp\u003e0.6 \u0026times; 10\u003csup\u003e4\u003c/sup\u003e cells were seeded into 96-well plates, and after adherent or addition of MPA treatment, cells were fixed and stained for proliferating cells using the EDU kit, and finally Hoechst -labeled cells were used for statistics.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec19\" class=\"Section2\"\u003e \u003ch2\u003eEvaluating cellular apoptosis by flow cytometry (FCM)\u003c/h2\u003e \u003cp\u003eAfter cells were attached or treated with MPA for 48h, cells were collected for apoptosis. Then, we performed a cell apoptosis assay using a FACS flow cytometer and a FITC Annexin V Apoptosis Detection Kit (BD Bioscience Pharmingen, San Diego, CA, USA); the kit was used in accordance with the manufacturer\u0026rsquo;s instructions. Finally, data were analyzed by Cell Quest software (Becton Dickinson, Franklin Lakes, NJ, USA).\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec20\" class=\"Section2\"\u003e \u003ch2\u003eTranswell assay\u003c/h2\u003e \u003cp\u003eTranswell assays were performed in transwell inserts (8-\u0026micro;m pore size, BD Biosciences, USA) inserted into 24-well plates without or with Matrigel (BD Biosciences, USA). The upper chamber was coated with 200 \u0026micro;l of serum-free medium containing 8\u0026times;10\u003csup\u003e4\u003c/sup\u003e cells (for migration) or 12\u0026times;10\u003csup\u003e4\u003c/sup\u003e(for invasion), while the lower chamber contained 700 \u0026micro;L of medium supplemented with 20% FBS. After incubation at 37 \u0026deg; C for the appropriate time, cells that had migrated to the lower surface of the membrane were fixed with methanol, stained with 0.5% crystal violet, and observed and quantified under a light microscope.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec21\" class=\"Section2\"\u003e \u003ch2\u003eWound healing assay\u003c/h2\u003e \u003cp\u003e20\u0026times;10\u003csup\u003e4\u003c/sup\u003e cells were seeded into 24-well plates, and when the cell density reached 90%, the wound was scratched using a 10\u0026micro;l pipette tips, and the cells were cultured until they reached confluence and photographed at 0, 72, 144 h.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec22\" class=\"Section2\"\u003e \u003ch2\u003eXenograft model\u003c/h2\u003e \u003cp\u003eFour-week-old female BALB/c mice were injected with 1\u0026times;10\u003csup\u003e7\u003c/sup\u003e cells cells into the right armpit. When the tumor diameter was about 5 mm, they were randomly divided into 4 groups and treated with intraperitoneal injection of drugs according to the experimental design. For MPA, the dose was 100 mg/kg/ bodyweight; for ABX-1431, the dose was 1 mg/kg, and the control group received the same amount of DMSO. Mouse body weight and tumor size were measured every two days. Fifteen mice were treated with drugs, euthanized, and the tumors were removed. Tumor size\u0026thinsp;=\u0026thinsp;width\u003csup\u003e2\u003c/sup\u003e \u0026times; length/2. The animal experiments in our study were approved by the Ethics Committee of Shandong University.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec23\" class=\"Section2\"\u003e \u003ch2\u003eMeasure of ROS and inhibitor\u003c/h2\u003e \u003cp\u003eIntracellular hydrogen peroxide levels were measured using 2,7-dichlorodihydrofluorescein diacetate (DCFH-DA; Beyotime Biotechnology, China). The cultured cells were washed once and incubated with DCFH-DA (20 \u0026micro;M, 30 min). DHE fluorescence was detected with a fluorescence microscope. Experiments were performed using N-acetylcysteine (NAC) (Selleck Chemicals, Houston, TX, United States) as an ROS inhibitor.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec24\" class=\"Section2\"\u003e \u003ch2\u003eStatistical analysis\u003c/h2\u003e \u003cp\u003eData were analyzed using GraphPad Version 7.0 software.Statistical significance was determined by Student's t tests, one-way analysis of variance (ANOVA) and two-way ANOVA. All experiments were repeated at least three times. Statistical significance was set at \u003cem\u003eP\u003c/em\u003e\u0026thinsp;\u0026lt;\u0026thinsp;0.05.\u003c/p\u003e \u003c/div\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eFunding statement\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis work was supported by the National Natural Science Foundation of China [Nos. 81772778 and 81902654].\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthor contributions statement\u003c/strong\u003e \u003c/p\u003e\n\u003cp\u003eJ.J., C.P.Q, X.H.M and M.X. designed the paper. X.H.M and M.X performed and analyzed experiments and wrote the paper. K.G., R.S., Y.L. and W.L. analyzed part of data and reviewed the paper. J.J., C.P.Q, X.H.M. and M.X. designed, supervised, and analyzed experimental work and wrote the paper.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eEthics statement\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAll animal work procedures were approved by the Ethics Committee of the Shandong University Qilu Hospital.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eDeclaration of interest statement\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors declare that they have no conflict of interest.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eSiegel, R.L., Miller, K.D., Fuchs, H.E. \u0026amp; Jemal, A. Cancer statistics, 2022. \u003cem\u003eCA Cancer J Clin\u003c/em\u003e \u003cstrong\u003e72\u003c/strong\u003e, 7-33 (2022).\u003c/li\u003e\n\u003cli\u003eUshijima, K. et al. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. \u003cem\u003eJ Clin Oncol\u003c/em\u003e \u003cstrong\u003e25\u003c/strong\u003e, 2798-803 (2007).\u003c/li\u003e\n\u003cli\u003eFerenczy, A. \u0026amp; Gelfand, M. The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia. \u003cem\u003eAm J Obstet Gynecol\u003c/em\u003e \u003cstrong\u003e160\u003c/strong\u003e, 126-31 (1989).\u003c/li\u003e\n\u003cli\u003eBlankman, J.L., Simon, G.M. \u0026amp; Cravatt, B.F. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. \u003cem\u003eChem Biol\u003c/em\u003e \u003cstrong\u003e14\u003c/strong\u003e, 1347-56 (2007).\u003c/li\u003e\n\u003cli\u003eChicca, A. et al. Chemical probes to potently and selectively inhibit endocannabinoid cellular reuptake. \u003cem\u003eProc Natl Acad Sci U S A\u003c/em\u003e \u003cstrong\u003e114\u003c/strong\u003e, E5006-E5015 (2017).\u003c/li\u003e\n\u003cli\u003eQin, H. \u0026amp; Ruan, Z.H. The role of monoacylglycerol lipase (MAGL) in the cancer progress. \u003cem\u003eCell Biochem Biophys\u003c/em\u003e \u003cstrong\u003e70\u003c/strong\u003e, 33-6 (2014).\u003c/li\u003e\n\u003cli\u003eNomura, D.K. et al. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. \u003cem\u003eCell\u003c/em\u003e \u003cstrong\u003e140\u003c/strong\u003e, 49-61 (2010).\u003c/li\u003e\n\u003cli\u003eViso, A., Cisneros, J.A. \u0026amp; Ortega-Gutierrez, S. The medicinal chemistry of agents targeting monoacylglycerol lipase. \u003cem\u003eCurr Top Med Chem\u003c/em\u003e \u003cstrong\u003e8\u003c/strong\u003e, 231-46 (2008).\u003c/li\u003e\n\u003cli\u003eCisar, J.S. et al. Identification of ABX-1431, a Selective Inhibitor of Monoacylglycerol Lipase and Clinical Candidate for Treatment of Neurological Disorders. \u003cem\u003eJ Med Chem\u003c/em\u003e \u003cstrong\u003e61\u003c/strong\u003e, 9062-9084 (2018).\u003c/li\u003e\n\u003cli\u003eJiang, M. \u0026amp; van der Stelt, M. Activity-Based Protein Profiling Delivers Selective Drug Candidate ABX-1431, a Monoacylglycerol Lipase Inhibitor, To Control Lipid Metabolism in Neurological Disorders. \u003cem\u003eJ Med Chem\u003c/em\u003e \u003cstrong\u003e61\u003c/strong\u003e, 9059-9061 (2018).\u003c/li\u003e\n\u003cli\u003eDeng, H. \u0026amp; Li, W. Monoacylglycerol lipase inhibitors: modulators for lipid metabolism in cancer malignancy, neurological and metabolic disorders. \u003cem\u003eActa Pharm Sin B\u003c/em\u003e \u003cstrong\u003e10\u003c/strong\u003e, 582-602 (2020).\u003c/li\u003e\n\u003cli\u003ePastushenko, I. \u0026amp; Blanpain, C. EMT Transition States during Tumor Progression and Metastasis. \u003cem\u003eTrends Cell Biol\u003c/em\u003e \u003cstrong\u003e29\u003c/strong\u003e, 212-226 (2019).\u003c/li\u003e\n\u003cli\u003eGu, C. et al. Inhibiting the PI3K/Akt pathway reversed progestin resistance in endometrial cancer. \u003cem\u003eCancer Sci\u003c/em\u003e \u003cstrong\u003e102\u003c/strong\u003e, 557-64 (2011).\u003c/li\u003e\n\u003cli\u003eZhou, Q. et al. DACH1 suppresses epithelial to mesenchymal transition (EMT) through Notch1 pathway and reverses progestin resistance in endometrial carcinoma. \u003cem\u003eCancer Med\u003c/em\u003e \u003cstrong\u003e8\u003c/strong\u003e, 4380-4388 (2019).\u003c/li\u003e\n\u003cli\u003eLiu, H., Zhang, L., Zhang, X. \u0026amp; Cui, Z. PI3K/AKT/mTOR pathway promotes progestin resistance in endometrial cancer cells by inhibition of autophagy. \u003cem\u003eOnco Targets Ther\u003c/em\u003e \u003cstrong\u003e10\u003c/strong\u003e, 2865-2871 (2017).\u003c/li\u003e\n\u003cli\u003eLi, W. et al. Comprehensive bioinformatics analysis of acquired progesterone resistance in endometrial cancer cell line. \u003cem\u003eJ Transl Med\u003c/em\u003e \u003cstrong\u003e17\u003c/strong\u003e, 58 (2019).\u003c/li\u003e\n\u003cli\u003eMa, X. et al. Fatostatin reverses progesterone resistance by inhibiting the SREBP1-NF-kappaB pathway in endometrial carcinoma. \u003cem\u003eCell Death Dis\u003c/em\u003e \u003cstrong\u003e12\u003c/strong\u003e, 544 (2021).\u003c/li\u003e\n\u003cli\u003eHu, W.R. et al. Monoacylglycerol lipase promotes metastases in nasopharyngeal carcinoma. \u003cem\u003eInt J Clin Exp Pathol\u003c/em\u003e \u003cstrong\u003e7\u003c/strong\u003e, 3704-13 (2014).\u003c/li\u003e\n\u003cli\u003eBaba, Y. et al. Expression of monoacylglycerol lipase as a marker of tumour invasion and progression in malignant melanoma. \u003cem\u003eJ Eur Acad Dermatol Venereol\u003c/em\u003e \u003cstrong\u003e31\u003c/strong\u003e, 2038-2045 (2017).\u003c/li\u003e\n\u003cli\u003eGong, X. et al. Monoacylglycerol Lipase (MAGL) Inhibition Impedes the Osteosarcoma Progression by Regulating Epithelial Mesenchymal Transition. \u003cem\u003eTohoku J Exp Med\u003c/em\u003e \u003cstrong\u003e256\u003c/strong\u003e, 19-26 (2022).\u003c/li\u003e\n\u003cli\u003eYang, G., Shi, R. \u0026amp; Zhang, Q. Hypoxia and Oxygen-Sensing Signaling in Gene Regulation and Cancer Progression. \u003cem\u003eInt J Mol Sci\u003c/em\u003e \u003cstrong\u003e21\u003c/strong\u003e (2020).\u003c/li\u003e\n\u003cli\u003eRomero, Y. \u0026amp; Aquino-Galvez, A. Hypoxia in Cancer and Fibrosis: Part of the Problem and Part of the Solution. \u003cem\u003eInt J Mol Sci\u003c/em\u003e \u003cstrong\u003e22\u003c/strong\u003e (2021).\u003c/li\u003e\n\u003cli\u003eBao, M.H. \u0026amp; Wong, C.C. Hypoxia, Metabolic Reprogramming, and Drug Resistance in Liver Cancer. \u003cem\u003eCells\u003c/em\u003e \u003cstrong\u003e10\u003c/strong\u003e (2021).\u003c/li\u003e\n\u003cli\u003eBurczynski, M.E., Sridhar, G.R., Palackal, N.T. \u0026amp; Penning, T.M. The reactive oxygen species--and Michael acceptor-inducible human aldo-keto reductase AKR1C1 reduces the alpha,beta-unsaturated aldehyde 4-hydroxy-2-nonenal to 1,4-dihydroxy-2-nonene. \u003cem\u003eJ Biol Chem\u003c/em\u003e \u003cstrong\u003e276\u003c/strong\u003e, 2890-7 (2001).\u003c/li\u003e\n\u003cli\u003eCiaccio, P.J., Jaiswal, A.K. \u0026amp; Tew, K.D. Regulation of human dihydrodiol dehydrogenase by Michael acceptor xenobiotics. \u003cem\u003eJ Biol Chem\u003c/em\u003e \u003cstrong\u003e269\u003c/strong\u003e, 15558-62 (1994).\u003c/li\u003e\n\u003cli\u003eBurczynski, M.E., Lin, H.K. \u0026amp; Penning, T.M. Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase. \u003cem\u003eCancer Res\u003c/em\u003e \u003cstrong\u003e59\u003c/strong\u003e, 607-14 (1999).\u003c/li\u003e\n\u003cli\u003eNakajima, T. et al. Expression of 20alpha-hydroxysteroid dehydrogenase mRNA in human endometrium and decidua. \u003cem\u003eEndocr J\u003c/em\u003e \u003cstrong\u003e50\u003c/strong\u003e, 105-11 (2003).\u003c/li\u003e\n\u003cli\u003eLewis, M.J., Wiebe, J.P. \u0026amp; Heathcote, J.G. Expression of progesterone metabolizing enzyme genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinoma. \u003cem\u003eBMC Cancer\u003c/em\u003e \u003cstrong\u003e4\u003c/strong\u003e, 27 (2004).\u003c/li\u003e\n\u003cli\u003eJi, Q. et al. Selective loss of AKR1C1 and AKR1C2 in breast cancer and their potential effect on progesterone signaling. \u003cem\u003eCancer Res\u003c/em\u003e \u003cstrong\u003e64\u003c/strong\u003e, 7610-7 (2004).\u003c/li\u003e\n\u003cli\u003eWang, Y. et al. Roles of SIRT1/FoxO1/SREBP-1 in the development of progestin resistance in endometrial cancer. \u003cem\u003eArch Gynecol Obstet\u003c/em\u003e \u003cstrong\u003e298\u003c/strong\u003e, 961-969 (2018).\u003c/li\u003e\n\u003cli\u003eWang, S. et al. Mechanisms involved in the evolution of progestin resistance in human endometrial hyperplasia--precursor of endometrial cancer. \u003cem\u003eGynecol Oncol\u003c/em\u003e \u003cstrong\u003e88\u003c/strong\u003e, 108-17 (2003).\u003c/li\u003e\n\u003cli\u003eWang, Y. et al. Prolonged conservative treatment in patients with recurrent endometrial cancer after primary fertility-sparing therapy: 15-year experience. \u003cem\u003eInt J Clin Oncol\u003c/em\u003e \u003cstrong\u003e24\u003c/strong\u003e, 712-720 (2019).\u003c/li\u003e\n\u003cli\u003eChen, X. et al. Aberrant survivin expression in endometrial hyperplasia: another mechanism of progestin resistance. \u003cem\u003eMod Pathol\u003c/em\u003e \u003cstrong\u003e22\u003c/strong\u003e, 699-708 (2009).\u003c/li\u003e\n\u003cli\u003eLiu, Z. et al. Fractalkine/CX3CR1 Contributes to Endometriosis-Induced Neuropathic Pain and Mechanical Hypersensitivity in Rats. \u003cem\u003eFront Cell Neurosci\u003c/em\u003e \u003cstrong\u003e12\u003c/strong\u003e, 495 (2018).\u003c/li\u003e\n\u003c/ol\u003e"},{"header":"Supplementary Table","content":"\u003cp\u003esupplementary table 1 is not available with this version. \u003c/p\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"cell-death-and-disease","isNatureJournal":false,"hasQc":false,"allowDirectSubmit":false,"externalIdentity":"cddis","sideBox":"Learn more about [Cell Death \u0026 Disease](http://www.nature.com/cddis/)","snPcode":"41419","submissionUrl":"https://mts-cddis.nature.com/cgi-bin/main.plex","title":"Cell Death \u0026 Disease","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"ejp","reportingPortfolio":"Nature AJ","inReviewEnabled":true,"inReviewRevisionsEnabled":true},"keywords":"Endometrial adenocarcinoma, Progesterone resistance, MGLL, AKR1C1, ABX-1431","lastPublishedDoi":"10.21203/rs.3.rs-1745135/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-1745135/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eEndometrial cancer is a common gynecological malignancy. With the delay of female fertility, conservative treatment with progesterone has been an important option for patients trying to preserve reproductive function. However, the progesterone resistance becomes a huge challenge and it is urgent to clarify the mechanism so as to propose a potential target and inhibit the development of endometrial adenocarcinoma and progesterone resistance. MGLL, an important factor involved in lipid mobilization, is overexpressed in many tumors, however the biological function of MGLL in the development of endometrial adenocarcinoma and the process of progesterone resistance still remains unclear. In this study, we first found MGLL was highly expressed in endometrial adenocarcinoma specimens by bioinformatics analysis, RT-PCR and immunohistochemistry and then we found the expression was further increased in progesterone resistant samples. Through in vitro and in vivo experiments, we demonstrated that overexpression of MGLL promoted tumor proliferation, metastasis and the occurrence of progestogen resistance, knockdown MGLL inhibited tumor proliferation, metastasis and reversed progestogen resistance. In addition, knockdown of MGLL can sensitize endometrial adenocarcinoma cells to progesterone by affecting ROS generation and reducing the expression of AKR1C1. Finally, it was verified that ABX-1431, MGLL inhibitor, reversed progesterone resistance and enhanced the sensitivity of endometrial adenocarcinoma to progesterone both in vitro and in vivo. In conclusion, the high expression of MGLL is involved in the occurrence and development of endometrial adenocarcinoma and progesterone resistance. Targeted inhibition of MGLL by inhibitors may be an effective method for the treatment of progesterone resistance in endometrial adenocarcinoma.\u003c/p\u003e","manuscriptTitle":"ABX-1431 inhibits the development of endometrial adenocarcinoma and reverses progesterone resistance by regulating the MGLL-ROS/AKR1C1 pathway","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2022-07-01 19:53:52","doi":"10.21203/rs.3.rs-1745135/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"revise","date":"2022-07-19T10:27:57+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"This content is not available.","date":"2022-07-18T17:48:05+00:00","index":2,"fulltext":"This content is not available."},{"type":"editorInvitedReview","content":"This content is not available.","date":"2022-07-11T16:02:18+00:00","index":1,"fulltext":"This content is not available."},{"type":"reviewerAgreed","content":"This content is not available.","date":"2022-07-10T07:54:09+00:00","index":2,"fulltext":"This content is not available."},{"type":"reviewerAgreed","content":"This content is not available.","date":"2022-06-27T12:26:25+00:00","index":1,"fulltext":"This content is not available."},{"type":"reviewersInvited","content":"","date":"2022-06-24T07:09:57+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2022-06-14T08:53:47+00:00","index":"","fulltext":""},{"type":"checksFailed","content":"","date":"2022-06-13T08:46:38+00:00","index":"","fulltext":""},{"type":"submitted","content":"Cell Death \u0026 Disease","date":"2022-06-10T10:56:09+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2022-06-10T10:56:09+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"cell-death-and-disease","isNatureJournal":false,"hasQc":false,"allowDirectSubmit":false,"externalIdentity":"cddis","sideBox":"Learn more about [Cell Death \u0026 Disease](http://www.nature.com/cddis/)","snPcode":"41419","submissionUrl":"https://mts-cddis.nature.com/cgi-bin/main.plex","title":"Cell Death \u0026 Disease","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"ejp","reportingPortfolio":"Nature AJ","inReviewEnabled":true,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"5e40b557-156d-45a1-8e87-8dde59512887","owner":[],"postedDate":"July 1st, 2022","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[],"tags":[],"updatedAt":"2022-12-23T08:09:56+00:00","versionOfRecord":{"articleIdentity":"rs-1745135","link":"https://doi.org/10.1038/s41419-022-05507-z","journal":{"identity":"cell-death-and-disease","isVorOnly":false,"title":"Cell Death \u0026 Disease"},"publishedOn":"2022-12-23 05:00:00","publishedOnDateReadable":"December 23rd, 2022"},"versionCreatedAt":"2022-07-01 19:53:52","video":"","vorDoi":"10.1038/s41419-022-05507-z","vorDoiUrl":"https://doi.org/10.1038/s41419-022-05507-z","workflowStages":[]},"version":"v1","identity":"rs-1745135","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-1745135","identity":"rs-1745135","version":["v1"]},"buildId":"_2-kVJe1T_tPrBINL-cwx","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}